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1. Introduction 
 
1.1 Background 
Choline (2-hydroxy-N,N,N-trimethylethanaminium) is a water soluble, 
essential, quaternary amine (Blusztajn, 1998). This molecule is a critical part of 
acetylcholine, which acts as a neurotransmitter in many organisms. Activated 
choline metabolism is characterized by increased phosphatidylcholine, one of 
the most common phospholipids used in membrane formation (Zeisel, 2012). 
Choline’s main uses are for acetylcholine and phospholipid biosynthesis, but it 
is also oxidized to betaine, a methyl donor and osmolyte in the body. Choline 
can also be used as methyl donor in the synthesis of methionine, an essential 
amino acid (Vigneaud, 1940). Choline has multiple functions in the body and is 
involved in many physiological processes. It is an essential nutrient involved in 
the structure of cell membranes, primarily as a structural component of 
phospholipids. Choline is also involved in other process as cholinergic 
neurotransmission, lipid transport and methyl metabolism. Choline plays 
important roles in brain and memory development in the fetus and appears to 
decrease the risk of the development of neural tube defects (Shaw, 2004). 
Many aliments are source of this essential choline, including eggs, meat, and 
fish.  
Fig.1. Chemical structure of choline 
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1.2 Choline metabolism 
 
Choline is an essential nutrient for a normal function of all cells and is a 
major substrate of cell membranes phospholipids. The transformation of 
choline in phosphatidylcholine is a major step to form phospholipids of the cell 
membrane and phosphatidylcholine constitutes around the half of the 
membrane phospholipids (Zeisel, 1994). The intracellular enzymatic cycle of 
choline is called the “Kennedy pathway”. Activated choline metabolism is 
characterized by increased phosphocholine and total choline. The major 
molecular causes for this increase are a higher expression and activity of 
choline kinase alpha (Glunde, 2005), a higher rate of choline transport (Katz-
brull, 1996) and increased activities of phosphatidylcholine specific 
phospholipase C and D (Iorio, 2005). All these enzymes participate in the 
synthesis of the major membrane phospholipid phosphatidylcholine (Glunde, 
2004). The “cholinic phenotype” is being explored for radiological diagnosis, 
prognosis, monitoring treatment response and the development of novel 
therapies (Glunde, 2011).  
The first step in the choline pathway (fig.2) is the uptake of choline into 
cells by choline transporters. The first reaction phosphorylates choline to form 
phosphocholine; catalyzed by choline kinase (ChoK). Phosphocholine is then 
converted by phosphocholine cytidylyltransferase (CTP) to form CDP-choline 
(cytosine diphosphate-choline). CDP-choline is then metabolized into 
phosphatidylcholine by addition onto a diacylglycerol. Phosphatidylcholine can 
be degraded by different phospholipases (PL) as PLA, PLC and PLD and 
increased levels of choline and phosphocholine (Georges, 1989). Intracellular 
accumulation of choline is a necessary step to increase tumor cells number and 
proliferation. (Michel, 2006). 
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Fig.2. Choline pathway or Kennedy pathway: from choline uptake by 
transporters to phosphatidylcholine formation in the cell membrane. Adapted 
from Glunde, 2004. 
1.21  Choline transporters 
 
Choline is a charged hydrophilic cation and cannot pass into the cell by 
simple diffusion, which means that transport must be facilitated by some type 
of transporter. The transport of free extracellular choline into cancer cell can 
be a rate limiting step in phosphocholine formation (katz-bull, 1996). Choline is 
taken up into cell by four major classes of transporters; a high affinity choline 
transporter (CHT); a choline transporter like proteins (CTL), an organic cation 
transporters (OCT) and an organic cation/ carnitine transporter novel (OCTN) 
(Michel et al, 2006). 
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High affinity choline specific transporters (CHT) have CHT1 as major 
representative transporter. Those transporters are very active in the nervous 
system in cholinergic neurons. Those transporters are sodium dependent and 
this system is coupled to the biosynthesis of acetylcholine specific to neuronal 
tissue (Simon, 1976). 
Choline specific transporters like proteins are represented by CTL1 who is 
expressed in cancers of various origins: central nervous system, breast, colon, 
ovary or prostate (Yuan, 2006) The CTL family is composed of at least six genes. 
This choline transporters family is sodium–independent and has an 
intermediate affinity for choline and hemicholinium-3 (HC-3) as compared to 
CHT1 (O’Regan, 2000). 
OCT and OCTN are low affinity transporters for choline. Three OCT 
members (OCT1–3) and two OCTN members (OCTN1 and OCTN2) have been 
identified and broadly detected in human tissues. These transporters non-
specifically deliver choline for phospholipid synthesis (Wang, 2007). 
Based on the kinetics of choline uptake, increased choline transporter 
activation can contribute to phosphocholine accumulation (Eliyahu, 2007). 
1.22  Choline kinases 
 
Choline kinase (ChoK) is primarily located in the cytoplasm of cells. Three 
isoforms of ChoK (ChoKα1, ChoKα2 and ChoKβ) exist in mammalian cells and 
are encoded by two separate genes: ChoKα and Chokβ. Homodimeric or 
heterodimeric forms of ChoK are enzymatically active (Aoyama, 2004). ChoK 
catalyses the phosphorylation of choline using ATP (adenosine triphosphate) as 
a phosphate donor, producing phosphocholine (Aoyama, 2004). This step using 
ChoK can be rate-limiting and can take a regulatory role in phosphatidylcholine 
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(PtdCho) synthesis under some circumstances (Aoyama, 2004). The 
upregulation of ChoK activity in cancer probably results from an increase in 
ChoKα expression. Moreover, the activity of ChoKα was shown to be increased 
in human breast carcinomas compared with normal breast tissue (Ramirez de 
Molina, 2002). This overexpression has been reported in several human tumor 
derived cell lines of multiple origins: lung, colon prostate and others (Gallego-
Ortega, 2009; Ramirez de Molina, Rodriguez-Gonzalez, 2002). Increased 
enzymatic activity and overexpression of ChoKα is correlated with advanced 
histological tumor grade in breast carcinoma (Ramirez de Molina, 2002). ChoKα 
expression and activity is directly associated with increased cancer cells 
proliferation and malignancy, making of it a potential prognostic marker of 
some cancers (Ramirez de Molina, 2007). 
ChoKα and ChoKβ are similar in their primary sequence but they are 
implicated in different metabolic pathays. While ChoKα1 affects into both 
phosphatidylcholine and phosphatidylethanolamine synthesis, ChoKβ affects 
only phosphatidylethanolamine synthesis. Furthemore, the transformation 
capacity seems to be exclusive to the ChoKα isoform. ChoKβ overexpression is 
not sufficient to induce in vitro cell transformation or in vivo tumor growth. The 
proliferative and oncogenic activities are linked with ChoKα and this isoform is 
one of the major targets of the choline pathway for antitumoral treatment 
(gallego-ortega, 2009). 
1.23  Phosphocholine cytidylyltransferase (CTP) 
 
This enzyme catalyses the synthesis of CDP-choline from phosphocholine 
(PCho) and cytidine triphosphate. CDP-choline is an active choline intermediate 
of the choline pathway which forms the membrane lipid phosphatidylcholine 
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(PtdCho). Phosphocholine cytidylyltransferase catalyses a regulatory step in 
PtdCho synthesis in normal cells as well as in cancer cells (Kent, 1997). Four 
homologous isoforms of CTP exist in mammalian cells. The control of CTP 
activity is very complex and this control is linked to oncogenic signaling. For 
example, CTP activity is increased in liver tumorigenesis and in colon cancer 
which results in elevated PtdCho levels (Bell, 1998; Dueck, 1996). An increase in 
CTP activity could decrease the phosphocholine levels. However several 
enzymes as ChoK can increase intracellular PCho and counteract a possible 
depletion of cellular PCho levels, thereby facilitating enhanced cell growth 
(Bell, 1998). 
1.24  Phosphatidylcholine hydrolysis 
 
Specific phospholipase D (PLD) hydrolyses PtdCho to phosphatidic acid 
and choline; this hydrolysis produces intracellular free choline (Cho). PLD1 and 
PLD2 are crucial in cell proliferation, survival signaling, cell transformation and 
tumor progression (Buchanan, 2005). High levels of PLD activity can be 
correlated with aggressiveness in human breast cancer cells (Imamura, 1993). 
Specific phospholipase C (PLC) can hydrolyse PtdCho producing PCho and 
diacyl-glycerol.  The activation of PLC can partially cause a higher PCho levels 
linked to ovarian carcinogenesis (Spadaro, 2008). 
 
1.3 Aberrant metabolism of choline in cancer 
 
During malignant transformation and growth, there is a 
reprogrammation of lipid metabolism, in particular fatty acid synthesis 
(Swinnen, 2006; Menendez, 2007). The ultimate goal of these modifications is 
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to provide cellular biomass for accelerated tumoral growth (Hsu, 2008). This is 
also called the “cholinic phenotype” of tumors. 
Phospholipids play a dual role of basic structural components of 
membranes and substrates of reactions involved in key regulatory functions in 
mammalian cells (Vance, 2004). PtdCho, the most abundant phospholipid in 
eukaryotic cell membranes, can generate second messengers and mitogens, 
such as diacylglycerol (DAG), phosphatidic acid (PA), which is, in turn, a 
precursor of DAG and lysophosphatidic acid (LPA), arachidonic acid (AA) and 
lysophosphatidylcholine (LPtdCho), through three major catabolic pathways 
mediated by specific phospholipases of types C (PLC) and D (PLD), acting at the 
two distinct phosphodiester bonds of the PtdCho headgroup, and by 
phospholipase A2 (PLA2) in the deacylation reaction cascade (Fig. 3). PCho, 
either produced by choline kinase (ChoK) in the first reaction of the three-step 
Kennedy biosynthetic pathway, or via PLC-mediated PtdCho catabolism, has 
also been shown to be mitogenic by acting as a mediator of growth factor-
associated cell  proliferation  (Podo, 2011). 
1.31   Regulation of choline metabolism by oncogenic 
signaling 
 
Choline metabolism is known to be regulated by oncogenic signaling 
(Glunde 2011). Many studies indeed emphasize the complex reciprocal 
interactions between oncogenic signaling and choline metabolism. But, how 
and where PCho is involved in the growth signaling cascade, and its relationship 
with the induction of ChoK activity downstream of Ras activation, remain to be 
determined (Podo, 2011). Several relationships therefore exist between the 
PtdCho cycle and cell receptor-activated signal transduction pathways, with 
implications for the biogenesis and utilization of other lipids and phospholipids 
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(Podo, 2011). Some of the existing links between ChoK activation and Ras-GTP-
stimulated phosphorylation cascades, mediated by Ras-effector 
serine/threonine-specific protein kinase encoded by RAF-1 gene (Raf-1), Ral 
guanine nucleotide dissociation stimulator (Ral-GDS) and phosphoinositide 3-
kinase (PI3K) effectors, are depicted schematically in Fig. 3. 
 
Fig.3.  Schematic representation showing links between phosphatidylcholine 
(PtdCho) de novo biosynthesis and catabolism (yellow box) and some signal 
transduction pathways. PtdCho cycle metabolites: CDP-Cho (cytidine 
diphosphocholine); Cho (free choline); DAG (diacylglycerol); GPCho 
(glycerophosphocholine); Gro3P (sn-glycerol 3-phosphate); LPtdCho 
(lysophosphatidylcholine); PA (phosphatidic acid); PCho (phosphocholine). 
Adapted from Podo, 2011. 
Importantly, Yalcin et al. found in 2010 that small interfering RNA (siRNA) 
silencing of choline kinase expression in transformed HeLa cells (epitheloid 
cervix carcinoma cells) completely abrogated the high concentration of 
phosphocholine, which in turn decreases phosphatidylcholine, phosphatidic 
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acid and signaling through the MAPK and PI3K/AKT pathways. These 
simultaneous reductions decreased the anchorage-independent survival of 
HeLa cells. In addition, they confirmed the relative importance of phosphatidic 
acid for the pro-survival effect as phosphatidic acid supplementation fully 
restored MAPK signaling and partially rescued HeLa cells from choline kinase 
inhibition. Taken together, these data indicate that the pooling of 
phosphocholine in cancer cells may be required to provide a ready supply of 
phosphatidic acid necessary for the feed-forward amplification of cancer 
survival signaling pathways (Yalcin, 2010). 
a. MAPK pathway and choline cycle  
 
MAPK signaling is involved in key cellular functions, including 
proliferation, motility and apoptosis. A major component of MAPK signaling is 
represented by the reaction cascade involving Ras, c-Raf, the MAPK/ERK 
kinases MEK1/2 and the extracellular signal-regulated kinases ERK1/2 (Fig.3). 
This pathway, following Ras mutation, results in an aberrant activation of target 
proteins and transcriptional factors in about 30% of human cancers.  
Each of the enzymes involved in choline metabolism is known to be 
affected by the RAS pathway. Oncogenic RAS can activate ChoK and controls 
the transcription of CTP through the activation of the MAPK pathway (Ramirez 
Molina, Penalva, 2002; Bakovic, 2003). In addition, several oncogenes including 
RAS increase ChoKα activity, resulting in higher intracellular levels of 
phosphocholine (Ramirez de Molina, 2005). These elevated expressions can 
lead to enhanced PtdCho synthesis, enabling rapid cell proliferation and tumor 
growth. Moreover, platelet derived growth factor (PDGF) can stimulate the 
phospholipase expression to elevate PCho levels. This high level of expression is 
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combined with increased ChoK activity to activate the choline pathway (Plevin, 
1991). 
In the purpose, it has been shown that U0126, a MAPK inhibitor, induces 
a drop in phosphocholine by inhibition of choline uptake and phosphorylation 
(Beloueche-Barbari, 2005). Also, this MAPK inhibitor is able to block 
phosphocholine formation in human colon carcinoma cells by interfering with 
choline uptake and phosphorylation via choline kinase (Liu, 2002). These 
studies have shown that pharmacological inhibition of MAPK signaling in cancer 
cells can be associated with modulations of choline pathway, reduced tCho 
level that precedes effects on cell cycling.  
Another inhibitor of the MAPK pathway was shown by our group to 
significantly decrease the total choline peak after 2 days of treatment with 
sorafenib (Karroum 2013). This observation suggests that the action of 
Sorafenib as MAPKinases inhibitor could result in an indirect inhibition of the 
choline pathway. Indeed, inhibition of MAPK signalling can result indirectly in 
reduced PCho and tCho levels; this effect is primarily mediated by ChoK 
inhibition as a result of its reduced expression downstream of Hypoxia Induced 
Factor 1 activation (Glunde 2008). Sorafenib, also named BAY 43-9006 and 
Nexavar, is used for the treatment of renal cell carcinoma and hepatocellular 
carcinoma (Pratilas, 2010). It is a small molecule multi-targeted kinase inhibitor 
that blocks RAF/MEK/ERK pathway. This inhibitor has other biologically 
relevant targets including vascular endothelial growth factor receptors, platelet 
derived growth factor receptors, fibroblast growth factor receptor,… (Wilhelm, 
2004).  Sorafenib is therefore able to affect both tumor signaling and 
angiogenesis. Preclinically, Sorafenib shows broad-spectrum antitumor activity 
in renal, colon, hepatocarcinoma, breast, non–small cell lung, ovarian, thyroid, 
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pancreatic, and melanoma xenograft models, involving either antiproliferative 
and/or antiangiogenic effects of the drug (Wilhelm, 2006). Sorafenib has 
potential toxicities as cardiotoxicity, hand-foot skin reaction and rash, 
hypertension, gastrointestinal perforations,… The more common undesirable 
effects of Sorafenib are described as : infection, lymphopenia, anorexia, 
haemorrhage,… This multi kinase inhibitors has many targets and must be used 
with caution.   
b. PI3K pathway and choline cycle 
 
The type I PI3K pathway triggered by cell receptor stimulation and Ras 
activation, and also involving chemokines and adhesion molecules, mediates 
the conversion of phosphatidylinositol 4,5-bisphospate (PIP2) into 
phosphatidylinositol 3,4,5-trisphosphate (PIP3), which, in turn, acts as an 
effector of downstream cell signaling, including AKT phosphorylation (Fig.3) 
(Cantley, 2002). An aberrant PI3K pathway and altered expression of the 
antagonizing phosphatase and tensin homolog (PTEN) are involved in tumor 
progression, angiogenesis, invasion and cell survival (Vivanco, 2002) . 
Phosphoinositide-3-kinase (PI3K) pathway can also affect the choline 
metabolism and has an action on choline uptake in lung carcinoma cell lines 
(Wang, 2007). PI3K-AKT also affects ChoK activation (Ramirez de Molina, 
Penalva 2002). Knockdown of ChoKα with small interfering RNA leads to the 
attenuation of MAPK and PI3K-AKT signaling and is associated with the 
inhibition of cell proliferation (Yalcin 2010). Contrarily, ChoKα contributes 
through a positive feedback to increased MAPK and PI3K signaling (Glunde, 
2011). The inhibition of PI3K using PI-103, results in a significant decrease in 
treated prostate and colon carcima cells volume compared to controls. 
Monitoring the changes in phosphocholine and tCho levels by MRS may 
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provide noninvasive pharmacodynamic biomarkers of PI3K pathway inhibition 
and potentially of tumor response (Al-Saffar, 2010). 
c. HIF and choline cycle 
 
Stabilization of the subunit of hypoxia-inducible transcription factor-1 
(HIF-1) and upregulation of its target genes play an important role in the 
metabolic machinery by which cancer cells undergo adaptive responses to 
hypoxic conditions and maintain a high proliferative rate in the presence of an 
altered bioenergetic balance between downregulated oxidative 
phosphorylation and increased glycolytic rate (Semenza, 2013). HIF-1 can 
increase ChoKα expression within hypoxic environments, consequently 
increasing cellular PC and tCho levels within these environments. Cells that 
survive in a hypoxic environment are likely to demonstrate elevated PCho 
levels (Glunde, 2008). Glunde et al indicated that MRSI detection of tCho might 
prove to be a useful biomarker not only of tumor aggressiveness and 
progression but also of tumor hypoxia (Glunde, 2008). On cells, Glunde et al 
observed a significant increase of ChoK and phosphocholine at exposure to 
hypoxia. There is a colocalization between the ChoK and the hypoxia in tumors 
(Glunde, 2008). This study suggests that the hypoxia inducible factor (HIF-1) 
can bind the hypoxia response elements of ChoKα promoter to increase ChoKα 
expression within hypoxia environments (Glunde, 2008). This suggestion was 
confirmed by Bansal et al; the transcriptional control of choline 
phosphorylation is largely mediated via HIF-1α binding to the newly identified 
hypoxia response element 7 of the ChoKα (Bansal, 2012).  The inhibition of the 
MAPK signaling pathway resulted in reduced tCho levels mediated by ChoK 
inhibition as a result of its reduced expression of HIF-1 activation. HIF-1 is 
activated under hypoxic condition and degraded under normoxic condition. A 
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correlation was observed between region of high tCho levels and hypoxia in 
vivo due to the regulation of choline kinase by HIF-1 (fig.4) (Glunde, 2008). 
 
 
Fig.4.  (A)The hypoxia response element linked with the enhanced green 
fluorescent protein is activated by HIF-1 under hypoxic conditions. HIF-1α is 
degraded under normoxic conditions. The binding of HIF-1 with the hypoxia 
element results in green. (B) The green fluorescence and the corresponding 
spectroscopy imaging of tCho were coregistered. In the resulting overlay image, 
the tCho image has been rendered in red, whereas green fluorescence is shown 
in green so that colocalization becomes yellow. Adapted from Glunde, 2008. 
  
1.32  The choline cycle as a target in oncology 
 
a.  Inhibition of ChoKα  
 
ChoKα is an important potential target in the cholinic cycle. Lacal and al 
suggested ChoKα inhibition as an antitumour therapy (Hernandez-Alcoceba, 
B 
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1997). Lacal group developed the drug MN58b, a specific inhibitor of ChoKα 
(Rodrigez-Gonzalez, 2003).  
  
Fig.5. Inhibition of PCho production by MN58B on different human cell lines, this 
effect is correlated with the inhibition of proliferation. Adapted from 
Hernandez-Alcoceba 1999. 
This compound exhibits significant antiproliferative activity and induces a 
strong reduction of tumour growth in nude mice xenografts (Rodrigez-
Gonzalez, 2003; Rodrigez-Gonzalves, 2004).  MN58b shows more than 20-folds 
higher efficiency towards ChoKα1 than ChoKβ (Gallego Ortega, 2009). The 
treatment of a MDA-MB-231 (breast) carcinoma with this inhibitor results in a 
specific decrease of phosphocholine and tCho levels in tumors (Al-Saffar, 2006). 
These changes in metabolites have the potential to be qualified as non-invasive 
pharmacodynamic biomarkers for detecting tumor response following 
treatment with choline kinase inhibitors (Al-Saffar, 2006). The induction of 
apoptosis by inhibition of ChoKα is related to the specific and significant 
increase of intracellular pro-apoptotic ceramides (a product of sphingomyelin 
metabolism) in tumor cells (Rodríguez-González, 2005). Moreover the PI3K/AKT 
and ERK (Extracellular signal-regulated kinases from the MAPK pathway) 
signaling pathways can be inhibited by ChoK inhibitors (Chua, 2009). In vivo, 
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the ChoK inhibition slowed tumor growth through the inhibition of Akt 
phosphorylation (Chua, 2009). Pharmacological inhibitors targeting ChoKα 
result in tumor growth inhibition and apoptosis. Targeting ChoKα results in 
decreased PCho and tCho levels. A significant decrease of cell proliferation and 
induction of differentiation in human breast cancer cells and tumors xenografts 
was observed with ChoKα downregulation (Glunde, 2005).  ChoK is required for 
breast tumor progression and pharmacological inhibition of ChoK reduced 
tumor growth in breast cancer (Ramirez de Molina 2004). Moreover the down 
regulation of ChoK using siRNA resulted in low uptake and retention of choline 
(Nimmagadda, 2009). These results support the targeting of choline kinase and 
show the potential ability of non-invasive MRS and radiolabeled choline to 
detect choline pathway modulation and tumor sequestration of choline. ChoK 
silencing may provide an alternative to enhance the effect of anticancer drugs 
in malignant cells as 5-fluorouracil (5-FU) treatment. In colorectal cancer ChoKα 
inhibitors induce a down regulation of the levels of both thymidilate synthase 
(TS) and thymidine kinase (TK), contributing to the induction of apoptosis 
triggered by 5-FU treatment. The mechanistic basis for the synergism seems to 
rely on the finding that ChoKα inhibitors are modulating the levels of TS and 
TK1 enzymes which are related to 5-FU metabolization (de la Cueva, 2013). 
N-[2-bromocinnamyl(amino) ethyl]-5-isoquinolinesulphonamide (H-89) is 
a molecule used as a specific cyclic-AMP-dependent protein kinase A (PKA) 
inhibitor. It has been used extensively for evaluation of the role of PKA in the 
heart, osteoblasts, hepatocytes, smooth muscle cells, neuronal tissue, 
epithelial cells, …(Lochner, 2006). It has also been shown that H89 inhibits at 
least 8 other kinases (MAPKAP-K1b, MSK1, KBα, SGK, S6K1, ROCK II, AMPK, and 
CHK1), while having a relatively large number of PKA-independent effects 
(Lochner, 2006; Davies, 2000). H-89 has been reported to inhibit 
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phosphocholine production and ChoK activity in HeLa cell lysates (Aboagye, 
1999). In the presence of 10 microM H-89, choline kinase activity was inhibited 
by 36 +/- 7.6% in vitro (Wieprecht, 1994). However in plasmodium falciparum, 
the inhibition of ChoK using H89 failed and ChoK catalized the formation of 
phosphocholine as efficiently as control cells (Choubey, 2007). In his study 
Gabellieri et al tested the effect of H-89 on samples of purified ChoK and 
showed that H-89 is capable of directly inhibiting ChoK activity independently 
of PKA or any other targets in cell lysates of MDA-MB-231 breast, PC-3 prostate 
and HeLa cervical cancer cells and in solutions of purified human ChoK. This is 
an off-target effect for H-89 (Gabellieri, 2009). 
 
Fig.6. Chemical structure of Protein Kinase Inhibitor H-89; 5-
Isoquinolinesulfonamide (CAS 127243-85-0) 
 
 b.  Inhibition of choline transporters 
 
The choline transport is also proposed as a potential therapeutic 
anticancer agent.  Choline transport is required for cellular membrane 
construction and is a rate-limiting step for acetylcholine production (Lockman, 
2002). The choline transport can be inhibited using specific pharmacological 
inhibitors of the choline transporters as Hemicholinium-3 (HC-3) and 
Tetraethylammonium (TEA) (fig.7). HC-3, which inhibits low affinity sodium 
independent choline transport is not specific to choline transport and also 
inhibits ChoK (Hernandez-Alcoceba, 1997). TEA inhibits the organic cation 
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transporters. In prostate cancer cells, the choline uptake is reduced by 95% 
using hemicholinium-3 and by 20% using TEA. In prostate cancer cells, the 
uptake of choline is mediated by selective choline transporters other than by 
the OCT (Muller, 2009). 
C. Other modulations 
 
The inhibition of CTP activity is proposed to prevent CTP translocation to 
the membrane and as anti neoplasic therapy. This inhibition increases cellular 
PCho levels and decreases PtdCho level (Geilen, 1992; Jimenez-Lopez, 2002). 
The Miltefosine treatment, an inhibitor of CTP, has been approved for the 
topical treatment of cutaneous metastases of mammary carcinomas (Clive, 
1999) 
Phospholipase-D is involved in cell proliferation and oncogenic signaling; 
PLD can be a valuable target for therapeutic intervention in cancer (Glunde, 
2011). The anti oestrogen drug tamoxifen activates PLD and PLC and increases 
levels of DAG, PCho and phosphoethanolamine which may lead to change in 
cell growth (Cabot, 1997).  
Phospholipase-C inhibition reduced HER2 expression on the plasma 
membrane and induces antiproliferative effects. The D609 was shown to be a 
potent inhibitor of PLC in a dose-dependent manner and reduced PCho levels 
(fig.7) (Amtmann, 1996). D609 showed promising results in various animal and 
human cancer cells lines and transformed cells in vitro (Amtmann, 1987). 
However, in in vivo animal studies D609 exhibited only a little antitumor 
activity (Schick 1989). 
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Fig.7. Inhibition of choline cycle using pharmacological molecules or shRNA. 
Adapted from glunde, 2011. 
 
1.4 Imaging markers of response to treatment 
 
In oncology, tumor size measurements before and after treatment is the 
most widely used method for evaluating tumor response to treatment (Afaq, 
2010). However, reduction in tumor size usually occurs late after the start of 
treatment and is insensitive to early treatment effects. Moreover many of new 
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treatments are targeted towards specific metabolic pathway. Many of these 
drugs can be clinically active but may not result in significant reduction in 
tumor size (Afaq, 2010). For these reasons the RECIST size criteria (Response 
Evaluation Criteria in Solid Tumors) have potential limitations to evaluate the 
effectiveness of a treatment. If there is a reduction in tumor size, this may not 
necessarily translate to improved survival for the patient. 
There is therefore a crucial need to use non-invasive imaging to facilitate 
the evaluation of the responsiveness of experimental tumors in preclinical 
therapeutic studies. Because molecular and cellular changes precede 
macroscopic changes in tumor size, it would be ideal to have an assay that 
could quantify these changes in both clinical cancer therapeutics and preclinical 
drug trials. Early indicators of treatment response that could also provide 
information on the spatial heterogeneity of response would be of signiﬁcant 
beneﬁt for both experimental and clinical trials. 
In the purpose, molecular imaging has the potential to assess tumor 
response to anticancer treatment by addressing metabolic or hemodynamic 
changes that will occur earlier than changes in tumor size. Molecular imaging 
techniques may involve magnetic resonance imaging, computed tomography 
scan (CT), ultrasound, optical and radionucleide techniques.  In the purpose, 
measurement of tumor metabolism, vascularity, cellularity, and proliferation 
can be considered for assessing tumor response to anticancer treatment (Afaq, 
2010).  
1.41   Imaging tumor metabolism 
 
a. FDG-PET 
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Glucose metabolism can be assessed using Positron Emission 
Tomography and the uptake of the 18F-ﬂuorodeoxyglucose (FDG) tracer 
(Shields, 2006). This is based on the observation by Warburg, Wind, and 
Negalein (1927) that glucose metabolism is increased in many tumors. To date, 
FDG-PET is widely used in diagnosis, staging, and monitoring of therapy, as the 
method has unsurpassed sensitivity for detecting occult metastases (Shields, 
2006; Culverwell, 2011). By comparing the degree of tracer uptake on 
sequential studies before and after treatment, tumor response can be 
determined (Afaq, 2010). It is routinely used in the staging of lung cancer at 
many centers, and has found regular use in the assessment of melanoma, 
lymphoma, colon, breast, head and neck, esophageal cancer,… (Valk, 2003). In 
the clinical setting, FDG-PET is usually associated with an x-ray computed 
tomography (CT) to combine metabolic data with anatomic imaging obtained 
by CT scanning. More over PET/CT can be used as a predictor of early response 
to chemotherapy in locally advanced breast cancer patients, lymphoma, 
pediatric cancer, lung cancer, ... PET/CT plays important role in early 
assessment of treatment response in various cancer patients. A positive PET/CT 
scans after the completion of therapy is a strong predictor of residual disease, 
whereas, a negative study is associated with complete remission in these 
patients (Kumar, 2010). 
A limitation of FDG, however, is the fact that enhanced glucose 
metabolism is not speciﬁc for tumors alone. Indeed, enhanced FDG uptake has 
also been observed in muscle, brain, infected and inﬂammatory tissue (Direcks, 
2008). Also, importantly, some tumor types are non-glucose avid and lead to 
false negatives (Culverwell, 2011).   
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b.  Magnetic Resonance Spectroscopy 
 
Metabolic activity can also be evaluated using MR spectroscopy (MRS), a 
technique that can identify and quantify tumor metabolites. MRS uses the 
same general principles and equipment as MRI. However, while MRI builds 
images using signals from 1H nuclei in tissue water, present at high 
concentrations, MRS measures signals from magnetic nuclei of tissue 
metabolites such as choline, creatine, and lactate that are present at much 
lower concentrations. A number of nuclear magnetic resonance (NMR)-active 
isotopes are available for interrogation in vivo. The most common nuclei used 
are 31P and 1H, which generate spectra that are dominated by resonances from 
endogenous metabolites (Gillies, 2005). 13C-MRS however is used to monitor 
the uptake and metabolism of 13C-enriched metabolites and serves as a tool for 
monitoring the fate of the label, as it is incorporated into other metabolic 
intermediates such as glutamine and lactate in the case of 13 C-labeled glucose. 
When used in combination with imaging strategies, multinuclear MRS methods 
provide detailed biochemical information that can be directly correlated with 
anatomical features (Li, 2015). 
1H-MRS has the highest sensitivity and can detect many metabolites 
including lipids, creatine/phosphocreatine (PCr), glycolytic intermediates such 
as glucose, glutamine/glutamate and lactate, in addition to choline-containing 
compounds such as phosphocholine (PCho) and glycerophosphocholine (GPC) 
(Table 1). 31P-MRS, on the other hand, has particular value for studies 
concerned with tissue bioenergetics, pH and membrane turnover, it can detect 
the presence of bioenergetic metabolites such as nucleotide triphosphates 
(NTP), PCr and inorganic phosphate (Pi), in addition to membrane phospholipid 
metabolites including phosphomonoesters (PME), which comprise PCho and 
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phosphoethanolamine (PE), and phosphodiesters (PDE), which comprise GPC 
and glycerophosphoethanolamine (GPE) (Belouche-Babari, 2010). 
Istope Resonance 
frequency 
(MHz) at 2.3 T 
% Natural 
abundance 
Sensitivity 
relative to 
1H 
Monitoring of metabolite levels/fluxes 
and physiological parameters 
 
1H 100 99.985% 100 Choline phospholipid metabolism 
Glycolysis and products (lactate, alanine) 
Neutral lipid metabolism 
Amino acids 
pH intra- and extracellular 
31P 40.5 100% 6.6 Bioenergetics (NAD-) 
Phospholipid metabolism 
pH intra- and extracellular 
13C 25.1 1.107% 1.6 Flux of metabolites in biochemical 
pathways (glycolysis, metabolism,…) 
 
19F 94.1 100% 83 Fluorinated drug uptake and 
pharmacokinetics 
Metabolic pathways  with 19F substrate 
Oxygen tension 
pH 
 
Table 1.  Summary of commonly utilized isotopes to monitor cancer cell 
metabolism by MRS. Adapted from Podo, 2011. 
MRS profiles greatly contributed in the 1990s to the identification of the 
characteristics of altered choline-phospholipid metabolism in cancer cells and 
tissues, as a potential source of novel indicators of tumor progression and 
response to therapy (Podo, 1999). Elevation of the 1H-MRS resonances band at 
3.2 ppm, mainly as a result of the trimethylammonium headgroup of Cho-
containing metabolites. Therefore arising from the nine chemically equivalent 
protons in the highlighted choline–N(CH3)3 groups of Cho, PCho and GPC has 
been reported as a common feature in a large variety of cancers (fig.8). 
Changes in the MRS tCho spectral profile reflect altered contents and metabolic 
fluxes of phosphocholine (PCho), glycerophosphocholine (GPC) and free choline 
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(Cho) through the biosynthetic and catabolic pathways of the 
phosphatidylcholine (PtdCho) cycle (Podo, 2011). The two main contributors, 
phosphorylcholine and glycerophosphocholine cannot be separated due to the 
small chemical shift difference relative to the spectroscopic linewidths (de 
Graaf, 2007).  
Alterations in the levels of PCho and GPC can also be detected in the 31P-
MRS frequency ranges typical of phosphomonoester (PME) and phosphodiester 
(PDE) compounds, respectively, together with those of 
phosphatidylethanolamine (PtdE) derivatives, phosphoethanolamine (PE) and 
glycerophosphoethanolamine (GPE) (Podo, 2011). 
 
Fig.8. Choline metabolism investigated with 1H and 31P-MRS in tumour models, 
live cancer cells and cancer cells extracts (a). Chemical strucuctures of choline 
metabolites (b). The 3.2 ppm “total choline”(tCho) peak consists of choline 
(Cho), phosphocholine (PCho) and glycerophosphocholine (GPC), which can be 
resolved in high-resolution 1H-MRS spectra of tissue and cell extracts. Adapted 
from Glunde, 2011. 
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The interest in choline (tCho peak, detectable with both 1H and 31P-MRS) 
primarily comes from its utility as a biomarker for cancer staging and diagnosis. 
This was ﬁrst documented by Negendank (1992) who provided strong evidence 
for elevated phosphomonoesters in lymphomas and head and neck cancers. As 
stated above, choline compounds are precursors of acetylcholine and cells 
membrane; they are involved in phospholipid synthesis and reflect membrane 
turnover. However the interpretation of change in choline spectroscopy is 
complicated due to the multiple contributions (de Graaf, 2007). Nevertheless, 
elevated choline (reﬂecting increased membrane synthesis and a higher cell 
turnover) has been conﬁrmed for breast, prostate, colon, cervical, and brain 
cancers and metastases, among others. Changes in choline are associated with 
positive responses in cancers in vitro (Podo, 2011) and in animal models 
(Gillies, 2005; Beloueche-Babari, 2010; and Podo, 2011), summarized in table 2.  
The table below shows the described impact of different targeted 
therapies on major molecular targets cited in this work and their impact on 
metabolites measured by MRS. 
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Therapy Molecular 
target 
Metabolites changes in 
cells 
Metabolite changes in 
vivo/ex vivo 
Reference 
MN58b 
(derivative 
from HC-3) 
ChoK ↓phosphocholine ↓tCho 
↓ phosphocholine 
Al-Saffar, 
2006  
PX-478 Hif-1α  ↓tCho 
↓ phosphocholine 
↓Glycerophosphocholin
e 
Jordan, 
2005 
LY294002 & 
wortmannin 
PI3K ↓ phosphocholine 
↑glycerophosphocholin
e 
 Beloueche
-babari, 
2006 
U0126 MEK1 ↓ phosphocholine  Beloueche
-babari, 
2005 
Sorafenib MAPK  ↓tCho 
 
Karroum, 
2013  
H89 PKA, ChoK ↓ phosphocholine  Gabellieri,  
2009 
D609 PC-PLC ↓ phosphocholine  Iorio, 2010  
Docetaxel Antimitotic 
chemotherap
y – 
stabilization 
of 
microtubules 
 ↑ choline metabolites 
shortly after treatment 
(1-2 days) in sensitive 
tumors 
Van Asten, 
2015 
suberoylanilid
e hydroxamic 
acid 
Histone 
deacetylase 
inhibitor 
↑ choline kinase α 
↑ phosphocholine 
↑glycerophosphocholin
e 
 Ward, 
2013 
 
Table 2.  Non exhaustive summary list of MRS studies used to assess response to 
different classes of molecular-targeted therapies in pre-clinical tumour models. 
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Note that, if most of the time, decrease in choline metabolites is observed in 
response targeted agents, some inhibitors do show an increase in choline 
metabolites. Adapted from Beloueche-Babari, 2010. 
Even if there is an accumulation of in vitro and in vivo data suggesting 
choline as a marker of response to treatment, interpretation of the tCho 
spectral proﬁle in terms of pharmacodynamics biomarkers of targeted 
therapies is, however, made rather complex by the dual role of each tCho 
component as both substrate and product in PtdCho cycle pathways. Indeed, 
Cho can enter the Kennedy pathway following transport from the external 
medium, or PLD-catalyzed PtdCho hydrolysis, or phosphodiesterase (PD)-
mediated GPC degradation; PCho, either synthesized by Cho phosphorylation 
or produced by PLC-mediated PtdCho degradation, acts as a substrate for the 
second reaction of the Kennedy pathway, catalyzed by CTP: phosphocholine 
transferase or cytidylyltransferase in the key regulatory step of PtdCho 
biosynthesis; and, ﬁnally, GPC, generated by PtdCho deacylation, can also act 
as a substrate for PD-mediated hydrolysis into Cho and sn-glycerol 3-phosphate 
(Gro3P) (Fig. 3). Therefore, elevation or reduction in the contents of PCho and 
tCho in cancer cells during tumor progression, or in response to therapy, may 
actually reﬂect a multiplicity of alterations taking place at the genetic, 
transcriptional, epigenetic and post-transcriptional levels (Podo, 2011). 
From a clinical perspective, choline 1H-MRS is also considered for tumor 
staging and monitoring. Most of clinical magnetic resonance scanners are 
equipped with sequences for spectroscopy measurements. The addition of 
spectroscopy to standard MRI techniques can significantly increase the 
sensitivity up to 88%, the specificity to greater than 90%, and the diagnostic 
accuracy up to 91% (Glunde and Bhujwalla, 2011). Choline metabolites can be a 
robust biomarker and can help to identify a lesion or to evaluate the efficacy of 
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a treatment. The proton spectroscopy of tCho can assist in diagnosing cancer 
and in specifying the margin of a breast tumor (Jacobs, 2004). The tCho 
spectrospy of the brain permits to distinguish tumor recurrence from necrosis 
(Wald, 1997). 
Detecting the early response of a tumor to treatment is very important 
to reduce damage with normal tissue in patient with non-responding tumors 
(Glunde and Bhujwalla, 2011). Changes in tCho can help to detect early 
response after a treatment and possibly predict tumor response based on tCho 
signal in patients with advanced breast cancer who responded or not to 
neoadjuvant chemotherapy (Danishad, 2010). Anticancer treatments leading to 
apoptosis or necrosis induced characteristic decreases in choline metabolites 
(Evelhoch gillies, 2000). 
tCho and other metabolite intensities can be translated into 
metabolomic profile and help to determine the tissue type. Metabolomic has 
the potential to detect lesions, guide biopsy, and to identify other conditions of 
malignancy, such as tumor aggressiveness (Wu, 2010). 
1.42   Imaging cell death  
 
As the cell undergoes apoptosis, there are a number of potential steps in 
the process that could be imaged: increase in cellularity with DW-MRI, or 
cytoplasmic lipid droplets associated with changes in the lipid structure during 
programmed cell death using 1H-MRS. 
Among those techniques, diffusion weighted MRI can assess tumor 
cellularity non-invasively (see section 1.54). DW imaging has indeed become a 
major contrast for tissue assessment by MRI (Bammer,2003; Norris, 2001) since 
the demonstration of the remarkable sensitivity of water diffusion to ischemia 
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in the brain, which prompted clinical interest in this novel MRI contrast. This 
technique is based on the mobility of water (or Apparent Diffusion Coefficient 
of water, ADCw) in a tissue. ADCw values are dominated by the presence of 
diffusion barriers (restriction effects). DW-MRI depends on the random small 
movements of water in the body. In the absence of barriers, these Brownian 
movements are totally free. The movement of water molecules in biological 
tissues is influenced by the cellular environment and by the integrity of 
membrane. The degree of restriction to water diffusion in vivo can be inversely 
correlated to tissue cellularity (Koh, 2007). The physical diffusion coefficients of 
intra- and extracellular water are not known with certainty. Nevertheless, 
because water is ‘trapped’ (on the NMR timescale) inside of the cells, the 
apparent diffusion of water within the cells is lower than that in the 
extracellular space. Hence, the measured ADCw is sensitive to cellularity. DW-
MRI primarily reports on loss of cellularity (fig.9), which is the ultimate 
outcome not only of extensive necrosis (Koh, 2007) but also of other types of 
cell death, including apoptosis and mitotic catastrophe (Morse, 2007). Early 
and significant changes in ADCw can occur in case of mitotic catastrophe, lytic 
necrosis or apoptosis. All the changes in ADCw may be considered as a 
generalized measure of cytotoxic response to chemotherapy (Morse, 2007), 
although no assumption can be made on the type of cell death involved.  
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Fig.9. A restricted motion of water due to high cellularity (situation A) can 
influence the ADCw to lower value. The situation B represents a lower cells 
density and a higher ADCw. Adapted from Guimaraes, 2014. 
Treatment of tumors may result in damage and/or killing of cells, thus 
altering the integrity of cell membranes or size of cells, thereby increasing the 
fractional volume of the interstitial space. These changes have been shown to 
increase the diffusion of water in the damaged tumor tissue (Kauppinen, 2002; 
Moffat, 2004; Ross, 2003). Successful anticancer therapies are correlated to 
early increases in tumor ADCw in both animals and humans (Jordan, Runquist, 
2005). This is likely a consequence of reductions in cell volume, which are a 
general response to effective chemotherapy. Thus, by quantifying tumour 
ADCw before and after anticancer therapies, tumor response or lack of 
response to treatment can be determined. (Afaq, 2010). 
Changes in the ADCw of tumors often precede any measurable change 
in tumor size or volume (Koh, 2007).  Hence, determination of ADCw changes 
could be an advantageous tool for evaluating changes in the tumor 
A 
B 
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microenvironment before and after treatment (Koh, 2007). Moreover, in the 
clinical practice, the measure of ADCw allows much earlier adjustments in 
cancer therapy. In many cancers, an increase in ADCw has been reported within 
the first two weeks after the start of chemotherapy, radiotherapy or novel 
therapeutics and was correlated with tumor response to treatment (Afaq, 
2010). Animal and clinical studies have shown that efficient treatments in many 
tumor types can be detected as an increase in tumor ADCw values due to the 
loss of cellular density (Thoeny, 2010). Many studies showed this characteristic 
increase of ADCw after different treatments, but a decrease of ADCw can also 
be observed. In different physiological or pathological conditions, cell swelling 
and shrinking changes the volume fractions of intra and extracellular spaces 
and lead to a drop in ADCw soon after initiation of a treatment, as summarized 
in Fig.10 (Jones, 2010 ; Afaq, 2010).  
In general, any pharmacologic or radioactive process that causes 
necrosis, mitotic catastrophe or apoptosis will lead to increase the water 
diffusion in extra-cellular spaces and the corresponding ADC value. Cell death in 
response to treatment precedes size change; therefore, DW-MRI may be an 
early biomarker of response for therapies that induce mitotic catastrophe, 
apoptosis or necrosis. However, changes in ADC may depend upon treatment 
as shown in the following figure. 
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Fig. 10. Chart summarises published studies using ADCw values to assess 
tumour response to chemotherapy (yellow), radiotherapy (red), 
chemoradiotherapy (green), hormonal therapy (purple) and targeted treatment 
(blue). The vertical axis shows tumour types and the horizontal axis indicates 
the timing of ADCw measurements (in weeks) after starting treatment. Each 
study is displayed across from top to bottom according to tumour types and 
indicated on the chart (author, year). Upward arrowheads indicate an increase 
in ADCw and downward arrowheads indicate a decrease in ADCw. In studies in 
which multiple ADCw measurements were taken, larger symbols indicate 
maximum ADCw change. Note that many studies showed an increase in ADCw 
values within 4 weeks of treatment. Furthermore, a number of studies showed a 
significant increase in ADCw values within 1 week of commencing therapy. 
Adapted from Afaq, 2010. 
 
 
INTRODUCTION 
Page | 46  
 
1.43   Imaging proliferation  
 
Thymine is the only nucleotide that is exclusively incorporated into DNA 
and not RNA, making of it and its nucleoside thymidine appropriate for 
studying DNA metabolism. In thymidine salvage, thymidine is transported 
across the cell membrane and phosphorylated by TK1 into thymidine 
monophosphate (TMP). The thymidine is further phosphorylated into  
thymidine diphosphate (TDP) and thymidine triphosphate (TTP) and then 
incorporated into DNA. Alternatively, using the de novo synthesis pathway, 
deoxyuridine monophosphate (dUMP) is converted to TMP which can then be 
further phosphorylated and incorporated into DNA. Similarly to thymidine, 
[18F]-Fluorothymidine (FLT) is transported into the cell and phosphorylated into 
[18F]-FLT monophosphate ([18F]-FLTMP) and trapped by TK1. [18F]-FLTMP can be 
further phosphorylated into [18F]- FLT diphosphate ([18F]-FLTDP) and [18F]-FLT 
triphosphate ([18F]-FLTTP). However, due to the substitution of OH with 18F in 
the 5-prime position, [18F]-FLTTP is not incorporated into the DNA. [18F]-FLT is 
trapped after phosphorylation by thymidine kinase 1, whose expression is 
increased in replicating cells (Muzi, 2005).  
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Fig.11.  [18F]-FLT PET serves as a surrogate of proliferation by targeting the 
activity of thymidine salvage, supplying DNA precursors to dividing cells. 
Adapted from McKinley, 2013. 
Studies on breast, lung, and brain tumors have demonstrated that retention of 
[18F]-FLT correlated with tumor proliferation (Tehrani, 2013). However, 
background uptake is high in the liver, bone marrow, and renal system, limiting 
the use in these organs. 
1.44   Imaging tumor hemodynamic parameters 
 
Since anticancer agents are sometimes targeted at the tumor 
vasculature, such as anti-angiogenic or anti-vascular drugs, there is a strong 
interest in monitoring response to these agents using non-invasive techniques 
that are able to assess tumor perfusion/vasculature or oxygenation status.  
Useful imaging systems have been developed to monitor angiogenesis 
and the microvasculature in vivo, including dynamic contrast enhanced 
magnetic resonance imaging (DCE-MRI) (Choyke, 2003; Afaq, 2010), PET and 
single photon emission computed tomography (SPECT), CT, Doppler ultrasound, 
and optical imaging methods (Jennings, 2008; Afaq, 2010).  
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DCE-MRI is the acquisition of serial MR images before, during, and after 
the administration of an intravenous contrast agent (CA) that produces time 
series images that enable pixel-by-pixel analysis of contrast kinetics within a 
tumor. The change in signal intensity after contrast administration is used to 
evaluate vascular parameters. DCE-MRI is used to evaluate the effects of drugs 
that modulate tumor vasculature, such as anti-angiogenic and anti-vascular 
treatments (Padhani, 2005). 
Non-invasive MR techniques are also able to assess tumor oxygenation, 
including 19F-MR oximetry and Electron Paramagnetic Resonance Oximetry. An 
adequate blood circulation is necessary for adequate supply of oxygen to all 
tissues. 
1.45   Imaging tumor metabolism 
 
MR spectroscopy (MRS) can be used to investigate biochemical changes 
associated with disease, but a limitation is the low sensitivity of this method for 
nuclei other than proton (Radda, 1986). 13C-MRS is a method of choice to image 
metabolic substrates. Dynamic nuclear polarization (DNP) can increase the 
sensitivity of in vivo 13C-MRS. For this, 13C labelled metabolites must be 
hyperpolarized; this method increases the 13C signal by >10 000 folds (fig.16) 
(Ardenkjaer-Larsen 2003). DNP transfers high electron spin polarization to 
nuclear spins via microwave irradiation in a strong magnetic field and at 
cryogenic temperature. Using this technique, dynamic changes in metabolic 
processes can be monitored (Jeffrey, 1991). The first clinical trial using 13C-MR 
metabolic imaging has been successfully performed in patients with biopsy-
proven prostate. There were no dose limiting toxicities observed with 
hyperpolarized 13C pyruvate (Nelson, 2013). This emerging method is able to 
INTRODUCTION 
Page | 49  
 
assess disease activity and contribute to decisions concerning patient care. It 
constitutes the basis for designing additional human studies in other cancers 
and for evaluating response to therapy. Because hyperpolarized MRI does not 
require a radiation dose for the patient, it could be used for serial monitoring 
to detect recurrence at early stage (Brindle, 2011). The principal drawback of 
the method is the short half-life of the polarization which is maximum 1 
minute. 
 
 
Fig.16. 13C spectrum of urea (natural abundance 13C) at 9.4 T and room 
temperature after an acquisition of 65 hours and the same sample 
hyperpolarized by the DNP-NMR method after an acquisition of 6 seconds. 
Adapted from Ardenkjaer-Larsen 2003. 
Practically, after hyperpolarization of the 13C enriched substrate, the 
enriched liquid is immediately injected into the mouse and the tumor is imaged 
in the MR magnet (fig.17) (see section 1.53 for technical aspects of 
hyperpolarization). 
a.          13C-pyruvate to 13C-lactate conversion 
 
To date, pyruvate has been the most commonly marker used for DNP. 
Pyruvate is a diagnostic marker in cancers because he is abundantly converted 
to lactate through anaerobic glycolysis in these conditions (fig.18) (Golman, 
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2006). Lactate labelling results from the reaction catalysed by the enzyme 
lactate dehydrogenase (LDH). The velocity of this reaction will depend on the 
delivery of hyperpolarized pyruvate to the tumor, the rate of pyruvate 
transport across the cell membrane and the kinetic of LDH (Brindle, 2011). The 
decrease in LDH-catalysed reaction can be explained by a loss of coenzyme 
NAD(H) due to the decrease in tumor cellularity, and reduced LDH 
concentrations (Brindle, 2008). There are increasing evidences for an early 
reduction in pyruvate-lactate exchange in a range of cancer models following 
treatment with cytotoxic chemotherapy (Witney, 2010 ; Day, 2007), targeted 
drug (Bohndiek, 2010 ; Dafni, 2010 ; Ward, 2010), radiotherapy (Day, 2011) and 
MAPK inhibitor (Lodi, 2013). A lot of studies support the pyruvate to lactate 
ratio as a biomarker of cancer aggressiveness, metastatic potential and 
response to treatment (Sriram, 2015). In another study, the response to 
treatment detected using hyperpolarized pyruvate is compared with the 
response detected from measurements of FDG uptake. After 24 hours of 
treatment the decrease in FDG uptake and the decrease in pyruvate to lactate 
ratio were comparable (Witney, 2009). Moreover, in prostate cancer cells 
significant changes of lactate/pyruvate (Lac/Pyr) are used to evaluate early 
response to radiotherapy. The decrease in Lac/Pyr ratio is mainly attributed to 
the decrease in LDH activity due to cell death caused by irradiation (Saito 
2015). 
Pyruvate, the end product of glycolysis, can be reduced by the NADH 
produced in the pathway to generate lactate, in the reaction catalyzed by the 
enzyme LDH. Alternatively, pyruvate undergoes transamination with glutamate 
to form alanine. Both reactions are readily reversible in the cell. A third 
reaction involves the irreversible decarboxylation of pyruvate to hyperpolarized 
13C-labeled carbon dioxide (Kurhanewicz, 2011). In pancreatic cells, the p53 
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status can be used as a biomarker to predict the sensivity to LDH inhibition. A 
mutant p53 tumor exhibited increased apoptosis, a lower 13C-lactate 
production after administration of treatment and reduced proliferation 
(Rajeshkumar, 2015). 
 
Fig.17. Transformation of 13C pyruvate in 13C lactate using the enzyme lactate 
dehydrogenase, in 13C alanine by alanine transaminase , in 13C carbon dioxide in 
a reaction catalysed by pyruvate dehydrogenase. Adapted from Kurhanewicz, 
2011. 
In cancer cells, the aerobic glycolysis is often enhanced (Warburg effect) 
with increased transcriptional regulation of a number of glycolytic enzymes 
including lactate dehydrogenase (LDH). Increased regulation has been shown to 
drive both tumor growth and the spread of metastases. Moreover, Warburg 
effect is associated with poor outcome in cancer (Hanahan, 2011). The 
reduction in the Warburg effect during PI-103-induced autophagy (PI3K / mTOR 
inhibitor) could result in a concomitant reduction in intracellular and excreted 
lactate. The autophagy induced in cancer cells by PI-103 could affect glycolytic 
metabolism reducing the formation of lactate.  The measurements of the rate 
constant of pyruvate to lactate exchange by DNP and 13C-MRS could provide a 
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valuable biomarker to monitor the effects of the PI-103 drug in longitudinal 
studies. The change in lactate could provide an indicator of metabolic 
processes accompanying drug induced autophagy. The drug-effects can be 
monitored through the use of hyperpolarized pyruvate (Lin, 2014). 
The injected hyperpolarized 13C-labeled pyruvate generates a 13C signal 
that is linearly proportional to its concentration.  The conversion of pyruvate to 
its metabolites, including lactate occurs within a minute of injection. This 
timing is short and corresponds to the unrecoverable decay of hyperpolarized 
products due to T1 relaxation and radio frequency excitation. The rate constant 
for pyruvate to lactate conversion can be significantly influenced by metabolic 
activity in tissues, by perfusion and by a rapid reduction of tumor oxygenation 
(Khegai, 2014 ; Bluff, 2015). Importantly, recent findings indicated that lactate 
labeling could result not only from net conversion of pyruvate into lactate, but 
also from exchange of the hyperpolarized 13C label between the injected 
hyperpolarized 13C pyruvate and the endogenous lactate pool (Brindle, 2015). 
There is now considerable evidence for a significant exchange contribution 
(Brindle, 2011). The chemical shift value is 183 ppm for lactate and 171 ppm for 
pyruvate (fig.19). 
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 Fig.18. Evolution of lactate and pyruvate peaks before and after treatment 
with Combrestatin-A4, a vascular targeting-agent. Adapted from Bohndiek, 
2010. 
 
b.                  13C-fumarate to 13C-malate conversion 
 
There are currently no techniques for directly and specifically imaging 
necrosis in vivo. 13C-magnetic resonance spectroscopy (MRS) can detect 
hyperpolarized fumarate to malate conversion catalysed by fumarase (fig.20). 
This reaction has been suggested as a marker of drug-induced cellular necrosis 
and treatment response in tumors (Gallagher, 2009). The malate outside of the 
tumor may reflect loss of tumor fumarase into the extracellular space of the 
surrounding tissue. Necrotic areas are likely to have poor perfusion and high 
extracellular fumarase activity where the plasma membrane permeability 
barrier has been compromised. In these particular conditions, the fumarate can 
be rapidly converted to malate (Gallagher, 2009). Healthy cells demonstrate 
slow fumarate transport through plasma membrane transport. Consequently, 
there is little detectable conversion of fumarate to malate within the short 
lifetime of the polarisation (Brindle, 2011). For example, the treatment of 
MDA-MB-231 cells with doxorubicin (a DNA intercalator) resulted in the 
production of significant levels of labelled malate by 72 h after drug treatment. 
There was no detectable labelled malate produced in untreated cells (Witney, 
2010). The levels of malate produced correlated with the levels of necrosis in 
vitro and in vivo (Gallagher, 2009; Witney, 2010). This method could therefore 
be used as a very early marker of necrosis (fig.21) (Bohndiek, 2010). The 
fumarase reaction is suitable as an in vivo biomarker of tissue necrosis because 
no coenzymes are required for the reaction, so even during cell death the 
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enzyme will continue to function (Gallagher, 2009). After injection of the 
fumarate, the signals from (1,4-13C2)fumarate, (4-
13C) malate and (1-13C) malate 
were seen at 176 ppm 181 ppm and 182 ppm respectively. 
 
Fig.19.   Krebs cycle with a focus on the transformation of fumarate into malate 
catalysed by fumarase. Adapted from Munir, 2001  
 
Fig.20.  Evolution of malate and fumarate peaks before and after treatment 
with Combrestatin-A4. Adapted from Bohndiek, 2010. 
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c.               Other major hyperpolarised substrates valuable in cancer 
monitoring 
 
Another hyperpolarised substrate that could be valuable in detecting 
tumor treatment response is 13C glutamine. Tumors show upregulated 
glutamine utilization due to the use of this amino acid for the generation of 
metabolic intermediates in the biosynthesis process, which supports the 
increased growth rate of tumor cells and the synthesis of anti-oxidant as 
glutathione (Cairns, 2011). The cellular oncogene MYC encodes a transcription 
factor which promotes cell proliferation. MYC up-regulates the expression of 
the glutamine transporters and the glutaminase activity (Gao, 2009). 13C 
glutamine can be used as a surrogate for MYC expression and to assess 
inhibition of tumour cell proliferation (Brindle, 2012). 
The metabolism of hyperpolarized glutamate to α-ketoglutarate, 
catalyzed by the enzyme alanine transaminase, may influence HIF-1 expression. 
HIF-1 is a transcription factor that facilitates tumor growth when oxygen is low 
and whose stability is regulated by α-ketoglutarate (Zhao, 2009). 
Hyperpolarised 13C glutamate can detect α-ketoglutarate in a tumor in vivo, 
raising the possibility to investigate on the role of α-ketoglutarate in controlling 
gene expression and HIF-1 stability in a tumor (Gallagher 2011 ; Brindle, 2012). 
The tumor extracellular pH can be imaged from the ratio of the signal 
intensities of hyperpolarised bicarbonate H13CO3¯ and 
13CO2 following 
intravenous injection of hyperpolarised H13CO3 ¯.  The technique was 
demonstrated in a mouse tumor model, which showed that the average tumor 
interstitial pH was significantly lower than the surrounding tissue. This 
technique can be used to image cancer which can be associated with alteration 
in tissue pH (Gallagher, 2008). 
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The tumor redox state can be determined by monitoring the oxidation 
and reduction of hyperpolarised 13C ascorbate and 13C dehydroascorbate, the 
reduced and oxidised forms of vitamin C. 13C ascorbic acid may find application 
in diseases, as inflammation, that lead to a high level of extracellular reactive 
oxygen species. The ascorbate oxidation is impossible in cancer because tumors 
have upregulated anti-oxidant systems to cope with the increased reactive 
oxygen species (ROS).13C dehydroascorbic acid provides a hyperpolarized probe 
to observe the rapid reduction to ascorbate and to hightlight redox status 
(Brindle, 2012). 
The technological improvements in nuclear magnetic resonance allow 
the analysis of biomarkers, which characterize tumor developments and tumor 
response. These techniques improve morphological data and diagnostic 
performances in oncology. For example, spectroscopy combined with diffusion 
weighted MRI allow to distinguish benign lesion from malignant tumor 
(Elshafey, 2014). Since those developments involve technological knowledge, 
the following section will briefly address the techniques underlying the 
parameters that have been described here above. 
 
1.5 Techniques 
 
1.51  ChoKα silencing using short hairpin RNA (shRNA) 
 
 These RNA molecules are used to silence target gene expression. The 
introduction of shRNA into mammalian cells through infection with viral 
vectors allows for stable integration of shRNA and long-term knockdown of the 
targeted gene (Moore, 2010). Once the small hairpin RNA is integrated in the 
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host genome, it is transcribed by the polymerase and exported from the 
nucleus by exportin 5. The mechanism of RNA interference is based on a post-
transcriptional process which leads to the sequence-specific degradation of 
host mRNA through the cytoplasmic introduction of double-stranded RNA 
identical to the target sequence (Fire, 1998). The double-stranded RNA is 
cleaved by Dicer generating small interfering RNAs formed by a guide strand 
and a passenger strand (fig.22). The endonuclease Argonaute 2 (Ago) catalyzes 
the unwinding of the small interfering RNA duplex. One strand of this duplex 
(the guide strand) is loaded into the RNA Interference Specificity Complex 
(RISC) while the passenger strand is released. The RISC then localizes the guide 
strand to the mRNA that has a complementary sequence leading to the 
endonucleolytic cleavage of the target (Elbashir, 2001). The target cleaved 
mRNA is further degraded by other endogenous nucleases. 
 
Fig.21.  Gene silencing : The shRNA is cleaved by Dicer. The “passenger strand” 
is cleaved by Ago and released. The “guide strand” is integrated in RISC. RISC 
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localizes the “guide strand” to the mRNA of interest leading to the cleavage of 
the target. Adapted from Kumar 2000. 
In our work, HEK293FT cells were transiently transfected with 
lipofectamine using a third-generation lentiviral system for lentivirus 
preparation. After 24h and 48h, viral supernatants were harvested, titrated, 
and used to infect target MDA-MB-231 cells. Selection was realized with 
puromycin (2 µg/mL). MDA-MB-231 cells were infected with lentivirus 
containing five short hairpin RNA’s (shRNA) targeting ChoKα (ThermoFisher 
Scientific ABgene; Epsom, Surrey – United Kingdom) (Porporato, 2014). The 
most effective shRNA (ID TRCN0000006050) was selected by western blot for in 
vivo experiments. Inhibition of ChoKα in MDA-MB-231 cells was compared with 
cells transduced with shRNA’s with a scrambled sequence (scr). Using shRNA, 
the inhibition of the ChoKα is very efficient and specific; it’s the best way to 
gene silencing. The use of a lentiviral vectors to target ChoK in a human 
breast cancer xenograft is very efficient. The downregulation of ChoK, which 
can be detected non-invasively with 31P or 1H-MRS, results in a reduction of cell 
proliferation and tumor growth (Krishnamachary, 2009). 
 
 1.52  Magnetic Resonance and 1H-MRS 
 
The information measured with magnetic resonance includes images, 
spectroscopy and spectroscopic imaging. The magnetic resonance is the 
absorption or emission of electromagnetic radiation by atoms in response to 
the application of a magnetic field. This technic is used to analyze the 
properties of matter and tissues. All atoms have an intrinsic nuclear motion of 
the nucleus call the spin. The manipulation of the spin orientation by a 
radiofrequency pulse is the basis of MR measurements. The MR signal is 
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obtained by placing a sample into an external field B0.  In these conditions 
spins rotate about an axis with a specific frequency called the Larmor 
frequency proportional to the magnetic field B0. At the Larmor frequency the 
nuclei absorb energy causing the proton to change its alignment and to be 
detected in a magnetic field. The MR signal intensity is reflected in the amount 
of energy emitted. To excite the nuclei in a required frequency range a radio 
frequency pulse with a selected bandwidth can be applied. When the radio 
frequency field matches the Larmor frequency at which the nuclear magnets 
naturally precess in the magnetic field B0, some of the nuclei are promoted 
from the low energy state to the high energy state. This single powerful pulse 
covers the whole frequency range and is commonly applied perpendicular to 
the applied magnetic field. The magnetization, disturbed from its orientation 
along the B0 axis, precesses in the XY plane, generating an oscillating signal, 
which is to be picked up by a receiver coil. This signal is called the free 
induction decay (FID). The MR signal is proportional to the number of nuclei 
contributing to it. The electron density in a molecule varies according to the 
type of nuclei and bonds in the molecule, therefore the net magnetic field vary 
with each nucleus. This phenomenon is also known as chemical shift and is the 
reason why different molecules are distinguishable in the MR spectrum as 
different peaks (Osorio-Garcia, 2011). 
MRS is used to obtain metabolic information in the form of a spectrum. 
The clinical applications of MR spectroscopy are the exploration of tissue’s 
metabolites to diagnose diseases or to monitor treatment response. For this in-
vivo approach we use spatial localization techniques to detect a signal from a 
specific volume of tissue within an anatomical region of the body (Salibi, 1998). 
Single voxel spectroscopy acquires a spectrum from a defined volume of tissue. 
This voxel of interest is defined by the intersection of three orthogonal planes. 
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There is an excitation of this volume of interest with frequency selective radio 
frequency (rf) pulses in techniques like point resolved spectroscopy (PRESS). 
Slice selective-rf pulses excite three intersecting orthogonal planes. The first 
slice is selected with a gradient and excited by a frequency selective 90° rf 
pulse. The second slice is selected using a 180° pulse; this pulse rephrases spins 
in the intersecting with slice 1. The third slice is select with gradient and a 180° 
pulse.  Only spins at the intersection with the third slice are excited by three 
pulses: a 90° excitation and two 180° refocusing pulses. Their net 
magnetization produces the final echo which is sampled and processed during 
PRESS frequency (Salibi, 1998). The signals obtained during the PRESS 
frequency correspond to a sum of complex-damped exponentials in the time-
domain, called the Free Induction Decay (FID) (Osorio-Garcia, 2011). 
To improve the acquisition many parameters of the FID can be modulate: 
- Repetition time : it’s the time between two excitation pulses applied 
on the same slice. 
- Echo time: It’s the time between the application of the excitation 
pulse  and the beginning of the signal’s peak in the coil. Depending 
echo time, we observe more slowly decaying components or 
metabolites. When the echo time is high (150 ms) the metabolites 
selected have a long T2. When the echo time is shorter (10ms) more 
metabolite resonances will appear in the spectra. There is 
superposition of number of peaks. 
- T1 or longitudinal relaxation time (fig.23): After a 90° pulse, the T1 
relaxation time is a measure of the return of magnetization following 
an exponential growth process to recover its ground state in the 
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direction of B0. Precisely the T1 is the time required to return to 63% 
of initial magnetization. 
 
Fig.22.  T1 relaxation after a 90° pulse or longitudinal relaxation curve. 
The recovery of magnetization is an exponential process with a time 
constant T1. This is the time at wich the magnetization has recovered 
to 63% of its value at equilibrium.  Adapted from Ridgway, 2010 
 
- T2 or transverse relaxation time (fig.24): After a 90° pulse, the T2 
relaxation time measures the progressive dephasing of spins. T2 is the 
decay to 37% of initial transverse magnetization. 
- T2* is the effective transverse relaxation time (fig.24). This parameter 
includes the transverse relaxation and inhomogeneities of magnetic 
field. These fluctuations are especially due to main field 
inhomogeneity and magnetic susceptibility in a sample.  
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Fig.23.  Transverse (T2 and T2*) relaxation. Both T2 and T2* are 
exponential processes with times constants T2 and T2* respectively. 
This the time at which the magnetization has decayed to 37% of its 
initial value immediately after the 90° rf pulse.  Adapted from 
Ridgway, 2010 
 
- Number of average: number of spectra acquired. This number can be 
increased to improve the quality of the spectrum and specially the 
signal to noise ratio.  
- Shimming: this step is crucial to correct the inhomogeneities of 
magnetic field. The tuning of different gradients pulses will improve 
the spectral resolution and permit to segregate the different 
metabolite resonances. The homogeneity of the field B0 is dependant 
of the first and second order shimming. The field homogenization is 
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also dependant of the size of the region to analyze and the tissues 
homogeneity. 
- Suppression of the water peak: to visualize the weak metabolites, a 
suppression of the big water peak is essential. Without this step, the 
water peak covers by his larger all the metabolite peaks. To suppress 
the water signal, specific radio frequency pulses centered on the 
resonance frequency of the water peak are applied in association with 
dephasing gradient. 
- Other parameters like magnetic field strength, type of coil used, 
distance between the region of interest and the coil or size of the 
lesion can influence the Free Induction Decay (Fayad, 2010). 
The transformation of the Free Induction Decay (time domain) in the 
frequency domain using the Fourier transform is necessary to observe the 
different peaks corresponding to the excited nuclei. The area under each peak 
allows the computation of the metabolite concentrations. In the spectrum, the 
variation in magnetic field strengths experienced by each molecule is related to 
their chemical shift, also called resonance frequency (Osorio-Garcia, 2011). 
Frequency differences are known as chemical shifts, are expressed in parts per 
million (ppm) and are independent of B0. On a spectrum, the X axis represents 
the chemical shifts of different metabolites. The Y axis represents the 
amplitude of the peak and is proportional to the among of metabolite. 
Moreover an in vivo spectroscopy measure must go along with an 
unsuppressed water signal. This water spectrum is used as reference for 
quantification. Relative concentration of the peak of interest is obtained by 
dividing the amplitude of peak by the water peak. 
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1.53  13C-MRS and Dynamic nuclear polarization (DNP)  
 
The hyperpolarization is a method to obtain strongly polarized nuclear 
spins (Ardenkjaer-Larsen, 2003). The dynamic nuclear polarization (DNP) is one 
of the most effective methods to polarize a wide range of systems. This DNP 
method enhances nuclear polarization using transfer of magnetization from 
electron to nuclear spins. This is a consequence of the strong coupling of the 
electron spin to the surrounding nuclei (Barnes, 2008). In 1953 Overhauser 
proposed that it was possible to transfer polarization to nuclei from electrons 
by saturating the electron transition (Overhauser, 1953). However this idea has 
been accepted 3 years later with the experimental verification of Carver and 
Slichter (Carver, 1956). This controversial mechanism is active when the 
electron resonance has a linewidth of the same order than the nuclear Larmor 
frequency. The shift in energy levels produced between spins is a hyperfine 
coupling; using this method the polarization of substrate will increase.  
Dynamic Nuclear Polarization is based on polarizing the nuclear spins in 
the solid state. The mechanism requires the presence of unpaired electrons 
added as free radical in a substrate. This free-radical doping agent is OX63 and 
must be present in the sample at micromolar concentrations during microwave 
irradiation in order to provide the needed nuclear polarization for 
intermolecular transfer (de Graaf, 2007). In order for the DNP process to be 
totally effective, the free radical must be homogeneously mixed within the 
sample. After cooling the sample, the high electron spin polarization is in part 
transferred to the nuclear spins by microwave irradiation (Ardenkjaer-Larsen, 
2003).  Under irradiation with microwave at the electron Larmor frequency, the 
transitions are stimulated and the nuclear polarization is increased. This 
transfer is increase at very low temperature (Ardenkjaer-Larsen, 2003). Indeed 
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the nuclear polarizations of 13C can be increased in a sample to almost 50% by 
placing him in a strong magnetic field at low temperature close to 0 Kelvin (de 
Boer, 1974). 
To illustrate the principle of DNP, consider nuclei at Larmor frequency 
ωN and electron spins with Larmor frequency ωe positioned in an external 
magnetic field B0 (fig.25A). When the nuclei and electrons will be completely 
separated, nuclear transitions can be achieved at frequency ωN. Electronic 
transitions are achieved at frequency ωe. However, when the electron 
generates a finite magnetic field at the nuclei, the two become dipolar-
coupled. The solid effect is represented by this dipolar interaction between an 
electron and a nuclear. This so-called hyperfine interaction will lead to a mixing 
of the states of energy, which in turn will lead to simultaneous electron and 
nuclear spin transitions or flips (de Graaf, 2007). The system is now irradiated 
at the microwave frequency (ωe − ωN). Besides a flip of the electron spin, the 
nuclear spin flips from an antiparallel to a parallel orientation (Fig.25B). 
However, due to fast electron T1 relaxation the spin quickly returns to the 
lowest energy level. Therefore, the combined effect of microwave irradiation 
and fast electron relaxation has led to a slight increase in polarization, as a 
single nuclear spin has been transferred from an antiparallel to a parallel 
orientation (Fig.25C). Continuing this process will lead to a complete depletion 
of the antiparallel state, giving complete or 100 % nuclear polarization (de 
Graaf, 2007). 
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Fig.24.  Scheme of the population of energy levels before and after 
hyperpolarization. The spectroscopic signal is proportional to the difference 
between the populations of nuclei in distinct energy levels. The 
hyperpolarization increases the NMR signal.  Adapted from de Graaf, 2007 
 
During polarization the sample must be kept cold while irradiated by 
microwaves in a strong magnetic field. DNP has been used as a polarization 
technique for organic molecules in the solid state. However, in vivo 
applications require the polarized material in the liquid state for injection into 
the subject. Ardenkjaer-Larsen et al. have offered a solution to this challenging 
problem (Ardenkjaer-Larsen, 2003). After polarization, the polarized solid 
material is brought into the liquid state by dissolution in an appropriate 
solvent, while preserving the large nuclear polarization (de Graaf, 2007). The 
polarized liquid is transferred to an injection syringe for immediate magnetic 
resonance acquisitions. The sample produced by DNP is an hyperpolarized 13C 
labeled compounds and allows the observation of reactions and metabolism in 
vivo and in vitro. 
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1.54  Diffusion Weighted-MRI 
 
Water diffusion sequence is adapted from a T2-weighted spin echo 
sequence. For this, a symmetric diffusion-sensitizing gradient around 180° 
refocusing pulse is applied (fig.26). Stationary molecules are unaffected by 
gradients and measured signal intensity is preserved. By contrast, moving 
water molecules acquire phase information from first gradient, which is not 
entirely rephased by second gradient, thereby leading to signal loss. Hence, 
water diffusion is detected as attenuation of measured MR signal intensity 
(Koh, 2007). The degree of water motion is proportional to the degree of signal 
attenuation (Koh, 2007). 
 
Fig.25.  Diffusion sequence and measurements of water motion are realised by 
the application of two gradients on either side of the refocusing 180° pulse.  
Adapted from Koh, 2007. 
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The sensitivity of diffusion is dependant of b-values. These parameters 
measure the degree of diffusion weighted applied, thereby indicating the 
gradient amplitude, the time of applied gradient, and the duration between the 
paired gradient (Koh, 2007). The change of b-values alters mostly the gradient 
amplitude. Water molecules with a large degree of movement will show signal 
attenuation with small b-values. By contrast, large b-values are usually required 
to perceive slow-moving water molecules or small diffusion distances in a high 
cellularity tissue (Koh, 2007). 
Using multiple b-values, the quantitative analysis can be performed and 
result in the calculation of the Apparent Diffusion Coefficient of water (ADCw). 
ADCw can be calculated by plotting the logarithm of the relative signal intensity 
of the tissue on the Y axis. The b-values are plotting on the X axis. A line can be 
fitted through the plots and the slope of this line describes the ADCw. The fit 
can be improved by using more b-values to reduce the error in ADCw 
calculation. The ADCw is calculated for each pixel and can be displayed as a 
parametric-map-(Koh,-2007). 
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Objectives of the thesis: 
The major goal of this study is focused on the validation of early in-vivo 
markers of response to therapies targeting the modulation of the choline 
pathway. These modulators are pharmacological inhibitors and specific shRNAs 
targeting choline kinase. Modulating the choline pathway, using specific 
targeted agents, represents a major challenge for current research efforts in 
oncology since this pathway is involved in tumor progression. Conventional 
anatomically based endpoints may be inadequate to monitor the tumor 
response to these targeted agents that usually do not result in tumor shrinkage 
while used as monotherapy. Therefore, the identification and use of more 
appropriate, combined biomarkers are needed to optimize the choice of 
treatments. These non-invasive biomarkers are particularly adapted for 
longitudinal monitoring and could be the key factor for treatment 
individualization and for managing tumor resistance. Among them, three non-
invasive imaging markers of tumor response are being benchmarked in 
response to choline targeted agents in the current work, and compared with 
classic histological methods and with therapeutic outcome in vivo in tumor 
xenografts:  
(i) 1H Magnetic Resonance Spectroscopy is used to assess the total 
choline level in tumors, wich is an indicator of the activity of 
choline pathway and membrane turnover. 
(ii)  Diffusion Weighted Magnetic Resonance Imaging is used to 
assess cell density and as a potential early indicator of 
therapeutic response.  
(iii) The dynamic monitoring of the conversion of hyperpolarized 
13C-fumarate into 13C-malate, and of hyperpolarized 13C-
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pyruvate into 13C-lactate, considered as emerging in vivo 
markers to evaluate treatment efficacy.   
  
RESULTS 
Page | 73  
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter III : Results  
RESULTS 
Page | 74  
 
 
  
RESULTS 
Page | 75  
 
1. MR spectroscopy can be used to investigate biochemical changes 
associated with cancer. This study validates the use of 1H Magnetic 
Resonance Spectroscopy and Diffusion Weighted Magnetic Resonance 
Imaging as early in-vivo markers of response to therapies targeting 
the modulation of the choline pathway in the breast cancer. 
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Novelty and impact statement: 
Sensitive and non-invasive biomarkers that correlate with efficacy are highly 
required in the transition towards individualized therapy in cancer. The current 
study identifies early markers of response to therapies targeting choline 
signaling, including 
1
H-choline spectroscopy as a pharmacodynamic biomarker, 
and DW-MRI as a marker of tumor response. Our data suggest that DW-MRI 
combined to choline spectroscopy may provide a useful non-invasive marker for 
the early clinical assessment of tumor response to therapies targeting choline 
signaling. 
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Abstract 
The cholinic phenotype, characterized by elevated phosphocholine and a high 
production of total-choline (tCho)-containing metabolites, is a metabolic 
hallmark of cancer. It can be exploited for targeted therapy. Non-invasive 
imaging biomarkers are required to evaluate an individual’s response to targeted 
anticancer agents that usually do not rapidly cause tumor shrinkage. Because 
metabolic changes can manifest at earlier stages of therapy than changes in 
tumor size, the aim of the current study was to evaluate 
1
H-MRS and diffusion-
weighted MRI (DW-MRI) as markers of tumor response to the modulation of 
the choline pathway in mammary tumor xenografts. Inhibition of choline kinase 
activity was achieved with the direct pharmacological inhibitor H-89, indirect 
inhibitor sorafenib and down-regulation of choline-kinase α (ChKA) expression 
using specific short-hairpin RNA (shRNA). While all three strategies 
significantly decreased tCho tumor content in vivo, only sorafenib and anti-
ChKA shRNA significantly repressed tumor growth. The increase of apparent-
diffusion-coefficient of water (ADCw) measured by DW-MRI, was predictive of 
the induced necrosis and inhibition of the tumor growth in sorafenib treated 
mice, while the absence of change in ADC values in H89 treated mice predicted 
the absence of effect in terms of tumor necrosis and tumor growth. In 
conclusion, 
1
H-choline spectroscopy can be useful as a pharmacodynamic 
biomarker for choline targeted agents, while DW-MRI can be used as an early 
marker of effective tumor response to choline targeted therapies. DW-MRI 
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combined to choline spectroscopy may provide a useful non-invasive marker for 
the early clinical assessment of tumor response to therapies targeting choline 
signaling. 
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Introduction 
Choline phospholipid metabolism is significantly increased in cancer 
cells. This specific cholinic phenotype is a new metabolic hallmark of cancer 
associated to elevated phosphocholine (PC) and increased production of total 
choline (tCho)-containing metabolites.
1, 2
 Choline kinase (ChK) is the first 
cytosolic enzyme of the choline pathway.
3
 This enzyme catalyzes the ATP-
dependent phosphorylation of choline to form PC, initiating the choline pathway 
for phosphatidylcholine (PtCho) biosynthesis
3
. In cancer, accumulation of 
intracellular PC is believed to reflect increased ChK activity. Chk induction is a 
general cellular response to growth factor stimulation, and is essential for cell 
growth and viability. Malignant transformation, facilitated by both ChK activity 
and PC production, is therefore characterized by abnormal choline metabolism.
4
 
At least three ChK isoforms exist in mammalian cells, which are encoded by 
two genes: choline kinase α (ChKA) and choline kinase β (ChKB). At least one 
isoform, probably ChKA, is involved in the promotion of cell growth during 
carcinogenesis. Therefore, inhibition of ChK activity may provide a novel 
strategy for the development of new families of targeted anticancer drugs.
5
 
In animal models, various pharmacological anticancer agents have an 
effect on phospholipid metabolism. In particular, ChK inhibition by RSM-932A 
and MN58b significantly decreases PC levels,
6, 7
 vascular disrupting agents such 
as 5,6-dimethyl-xanthenone-4-acetic acid induce a decrease in tCho,
8
 gene 
therapy as a treatment of glioma induces early apoptosis with a significant 
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accumulation of glycerophosphocholine (GPC) and PC,
9
 and radiation therapy 
can decrease tCho levels, as observed 24 hours after a 20 Gy X-ray dose.
10
 
Effective methods to characterize an individual’s response to treatment 
are mandatory to assess the therapeutic benefits of novel targeted therapies. 
Conventional, anatomically-based endpoints are deemed inadequate to monitor a 
tumor response to targeted agents that usually do not affect tumor size when 
used as a monotherapy. As an alternative, in vivo proton MR spectroscopy (
1
H-
MRS) is a non-invasive technique that can provide information on tumor 
metabolism for experimental investigation and, potentially, for tumor diagnosis 
and monitoring.
11, 12
 Metabolic changes can manifest at earlier times during 
therapy with respect to changes in tumor size.
13
 Hence, a rapid reduction in tCho 
levels (comprising mixed signals from choline, GPC and PC) has been proposed 
as a non-invasively marker of the tumor status and of inhibition of cellular 
proliferation.
13
 In this context, 
1
H-MRS imaging of tCho levels in many cancers, 
including breast cancer,
14
 have been performed and linked to tumor evolution 
and diagnostic performance. 
Besides 
1
H-MRS, diffusion-weighted MRI (DW-MRI) is another non-
invasive method than can be used to monitor the evolution of a tumor and its 
response to treatment. DW-MRI primarily reports on loss of cellularity, which is 
the ultimate outcome not only of extensive necrosis
15
 but also of other types of 
cell death, including apoptosis and mitotic catastrophe.
16
 Changes in the 
Apparent Diffusion Coefficient of water (ADCw) of tumors often precedes any 
RESULTS 
Page | 82  
 
measurable change in tumor size or volume.
15
 Hence, determination of ADCw 
changes may influence clinical practice by allowing much earlier adjustments in 
therapy.
17
 In many cancers, an increase in ADCw has been reported within the 
first two weeks after the start of chemotherapy or radiotherapy and was 
correlated with tumor response to treatment.
17
  
The aim of the current study is to evaluate tCho (detected with 
1
H-MRS) 
and ADCw (detected with
 
DW-MRI) as markers of the response of mammary 
tumor xenografts to the modulation of the choline pathway using direct and 
indirect ChK inhibitors in mice. 
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Material and methods 
Targetingof ChK activity 
MDA-MB-231 tumor-bearing mice (tumor volume: 0.2 ± 0.1cm
3
, see 
supplementary for tumor induction protocol) were intraperitoneally treated daily 
with a direct inhibitor of ChK activity (H89: 20mg/kg dissolved in 35µl of 
DMSO) for 5 days, an indirect inhibitor of ChK activity (sorafenib: 40mg/kg 
dissolved in 35µl of DMSO) for 5 days, or vehicle (DMSO, 35µl). H89 is used 
in this study for his direct and independent inhibition of ChK activity
18
, whereas 
sorafenib is a well-documented multi-kinase inhibitor.
19
 For ChKA silencing, we 
used short hairpin (sh)RNA (clone ID TRCN0000006050) from ABgene 
(Epsom, Surrey, United Kingdom). Scramble shRNA (shSCR) was used as a 
negative control. Cells were transfected as reported previously
20
 (see 
supplementary). Reduction in choline kinase expression was assessed by 
western blotting analysis (see supplementary). 
1
H-MR choline spectroscopy 
Animal experiments were performed with an 11.7-Tesla, 16-cm inner diameter 
bore system (Bruker, Biospec, Ettlingen, Germany) equipped with a quadrature 
volume coil (40-mm inner diameter). Animals (tumor volume: 0.2 ± 0.1cm
3
) 
were anesthetized by isoflurane inhalation (3% in air for initiation and 1–2% in 
air for maintenance). They were laid on a warm water blanket connected to a 
circulating water bath to maintain body temperature (checked using a rectal 
temperature probe). A pressure cushion was used to monitor breathing.  
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For single voxel spectroscopic data acquisition, volumes of interest were 
placed inside tumors according to T2-weighted reference images. 
Optimalization of magnetic field homogeneity (localized shimming) was 
performed until achieving a linewidth of water resonance below 50Hz. 
Automatic shimming and manual water suppression (VAPOR) were used. 
1
H-
MR spectra were acquired using a point-resolved spectroscopy (PRESS) 
localization technique. Typical acquisition parameters were repetition time 
(TR)=2.5s, echo time (TE)=20ms, averages=256, voxel size=4x4x4 mm
3
, and 
total acquisition time=10min50s. MR spectra were analyzed using jMRUI 
software version 5.0. Metabolite model signals used in quantitation based on 
quantum estimation (QUEST) were simulated in NMR-SCOPE (NMR spectra 
calculation using operators; jMRUI). Signals were imported in jMRUI, 
pretreated by Hankel Lanczos Singular Value Decomposition (HLSVD) in order 
to eliminate any residual water peak, and rephased. Model fitting was performed 
using the QUEST routine of jMRUI. Peak areas were measured for tCho peak 
(δ=3.21ppm) and normalized with the water peak area (δ=4.7ppm) from the 
non-water suppressed scans using a same volume of interest and geometry. 
DW-MRI 
For DW-MRI, a transverse echo planar imaging sequence was used with the 
following acquisition parameters: TR/TE=3000/27ms, duration of diffusion 
gradients (d)=7ms, separation of diffusion gradients (Δ)=14ms, slice 
number=12; slice thickness,=1mm, interslice distance=1.2mm, acquisition 
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time=5min24sec. DW images were acquired using b-values of 0-100-200-400-
600-800-1000-1200-1500s/mm 2. The b-value is equal to 𝛾2𝐺𝑑  
2 𝛿2 (∆ −
(𝛿 3⁄ )), where Gd is the strength of the diffusion-weighting gradient, and g is 
the gyromagnetic ratio for protons. Mean apparent diffusion coefficients 
(ADCw) were calculated from DW images and averaged for every slice where 
the tumor was found using a homemade program in Matlab software (The 
MathWorks Inc., Natick, MA, USA) to define regions of interest (ROI). The 
exponential decay of the signal as a function of the b-value was measured 
according to the Stejskal–Tanner equation. ADC maps were generated by 
nonlinear least squares regression of a mono-exponential to the experimental 
signal intensity for all b values. 
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Results 
Direct (H89) and indirect (sorafenib) targeting of ChKA decreases tumor 
choline content 
In mice bearing a MDA-MB-231 human breast cancer, we first quantified tumor 
tCho content non-invasively using single voxel 
1
H-MR choline spectroscopy. A 
significant decrease in the tCho to water ratio was observed after 48 hours of 
treatment with H89 (*, CI 0.06-0.72; n=6) and with sorafenib (**, CI 0.095-0.5, 
n=7) (Fig.1A). Decreases were still significant after 5 days (measurement at 108 
hours) of treatment (*, CI 0.02-0.7 and *, CI 0.027-0.41, respectively). In the 
control group (n=8), there was no significant change of the tCho peak during the 
5 days of monitoring (Fig.1A). Corroborating these in vivo data, ex vivo 
quantification of PC by mass spectrometry (HPLC-ESI-MS, see supplementary 
methods) of 4 tumors of each group did confirm the significant difference 
between control tumors and tumors treated with sorafenib or H89 (*, CI 0.17-
2.51; **, CI 0.67-3.00 respectively) (Fig.1B). The decrease in tCho and PC 
demonstrate a modulation of the choline cycle.  In this regard, ChKA expression 
was shown to be significantly decreased to 49,7% after treatment with sorafenib 
(**; n=4, independent experiments), and to 71,9% after treatment with H89 (*, 
n=4, independent experiments), with respect to control cells (supplementary 
Fig.1).  
In mice bearing shRNA-transfected MDA-MB-231 tumors, a significant 
decrease (p=0.003, n=9) was also observed in the tCho to water ratio when 
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comparing anti-ChKA versus SCR shRNA-expressing tumors (n=10) (Fig.1C). 
Again, ex vivo quantification of PC by mass spectrometry of 4 tumors of each 
group did confirm the significant difference between shSCR and shChKA 
tumors (***, CI -4.52/-1.80) (Fig.1B). ChKA expression was efficiently silenced 
by the specific shRNA, as shown by Western blot analysis in vitro on MDA-
MB-231 cells (Fig.1C). Typical 
1
H- MRS spectra from in vivo shSCR and 
shChKA tumors are shown in Fig.1D. Thus, both direct and indirect 
pharmacological inhibition of the choline cycle activity, as well as genetic 
targeting of ChKA expression, all significantly reduced the tCho content of 
MDA-MB-231 tumor xenografts in mice. Relative decreases in tCho tumor 
content were of -54.4% after 48h using H89, -49.3% after 48h using sorafenib, 
and -57.2% using anti-ChKA shRNA. Importantly, the results also illustrate the 
high heterogeneity in the basal tCho/water ratios from one tumor to another 
(large standard errors of the mean).  
Sorafenib, but not direct ChK targeting, decreases intratumoral cellularity 
In MDA-MB-231 tumor-bearing mice, intratumoral cellularity was assessed 
using DW-MRI and quantified from ADCw calculation
15
. No significant change 
in ADCw was observed following treatment with H89 (n=6), whereas sorafenib 
induced a progressive increase in ADCw that was significant after 5 days of 
treatment (**, CI -0.54-0.07, n=9) (Fig.2A), which is generally described to 
reflect a decrease in cellularity. Typical ADCw maps pre and post-sorafenib 
treatment are shown in Fig.2B. Similarly to H89 ChK inhibition, MDA-MB-231 
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tumor expressing an anti-ChKA shRNA had similar ADCw compared to those 
expressing SCR shRNA (data not shown). Thus, only sorafenib increased 
ADCw in MDA-MB-231 xenografts. 
Direct and indirect ChK targeting can induce tumor necrosis 
Tumors were harvested after 5 days of treatment. Hematoxylin and eosin 
staining of tumor slices revealed a significant increase in necrosis with sorafenib 
treatment (*, p=0.048, n=4; Fig.2C) with respect to control tumors (n=6). Anti-
ChKA shRNA also caused a significant tumor necrosis (*, n=4;  p=0.015), but 
not H89 (n=6) after 5 days of treatment (only a non-significant trend towards 
increased necrosis was seen).  Typical H&E stained tumor sections with or 
without treatment with sorafenib are shown on Fig. 2D. 
Direct and indirect ChK targeting can delay the tumor growth 
The impact of daily sorafenib and H89 administration on MDA-MB231 tumor 
growth was compared for 10 days with the growth of tumors in vehicle-treated 
mice. A significant tumor growth retardation was observed for sorafenib versus 
control treatment (*, p=0.02; n=3-4/group), but not for H89 versus control 
(n=10) (Fig.3A).  A significant tumor growth delay was also observed in anti-
ChKA versus SCR shRNA tumors (***, CI -686.5-134.5; n=8-10/group) 
(Fig.3B). Thus, sorafenib and anti-ChKA shRNA, but not H89, impacted MDA-
MB-231 tumor volume progression. 
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Discussion 
Most targeted therapies for cancer cause tumor stabilization rather than 
shrinkage, thus reducing the sensitivity or rendering inappropriate the standard 
metrics of response, including Response Evaluation Criteria in Solid Tumors 
(RECIST).
21
 There is therefore a need for alternative quantitative biomarkers of 
response. Among these, our study shows that tCho (measured using 
1
H-MRS) 
and ADCw (measured using DW-MRI) can be used to noninvasively assess 
metabolic tumor responses to treatments in vivo.  
Our data document that intracellular tCho levels can be determined non-
invasively in tumors with 
1
H-MRS in order to evidence ChK target inhibition. This 
pharmacodynamic parameter was suitable to demonstrate that treatments were 
acting on their targets. However, it was not suited to predict the response of a tumor 
to choline-targeted treatment, and additional imaging markers should be considered 
to predict the response of a tumor to treatment. This is illustrated in our study by 
the fact that, when targeting ChK activity with a direct inhibitor (H89), a significant 
decrease of tCho and PC was observed that was not associated with a drop of 
cellularity and a stabilization of tumor growth. Comparatively, we used sorafenib, a 
well-documented clinical multi-kinase inhibitor that primarily decreases the 
phosphorylation of extracellular signal-regulated kinase (ERK) in the mitogen-
activated protein kinase (MAPK) pathway,
19
 and also targets ChK activity. Daily 
injections of sorafenib at high dose induced a rapid (48-h) decrease in the tumor 
content of tCho and PC, which preceded decreased cellularity (measured with DW-
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MRI), necrosis and, ultimately, a reduction of tumor size (which became significant 
only 5 days post-treatment). In line with our findings, inhibition of MAPK 
signaling with the U0126 MEK inhibitor has been previously reported to cause a 
drop in intratumoral tCho and PC levels in tumors.
22
 Finally, targeting ChKA with 
a specific shRNA decreased tCho and PC levels in tumors. We found that the 
knock-down of the ChKA induces tumor necrosis and tumor growth retardation.  
We did not observed any significant difference in basal ADCw values between 
MDA-MB-231 tumor expressing an anti-ChKA shRNA compared to those 
expressing SCR shRNA. Indeed, Diffusion-Weighted MRI is adapted to a 
longitudinal follow up of individual tumors before and after treatment, which is not 
possible with this approach. Of note, our DW-MRI results were interpreted as a 
drop of cellularity, while other factors can contribute to ADCw changes, including 
tissue disorganization, extracellular space tortuosity, and integrity of cellular 
membranes that can also impact on motion of water molecules.
23
  
Publically available 
1
H-MRS data support variable independent 
conclusions regarding the usefulness of in vivo spectroscopy for monitoring the 
response of breast cancer to therapy. One source of variability is that choline 
transport rates and ChK activity are increased in breast cancer cells that express 
elevated levels of PC.
24
 Another source of variability could be attributed to the 
significant induction of ChK expression with the histological tumor grade.
25
 
Consistently, the association between ChK overexpression and tumor 
aggressiveness has been reported for ChK inhibition by small interfering RNAs
26
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and by the specific inhibitor MN58b.
6
 These studies nevertheless concluded that 
ChK inhibition significantly reduces PC and tCho levels in breast cancer cells, and 
proposed MRS to be used as a potential non-invasive marker of ChK inhibition and 
of tumor response to treatment. However,  authors also pointed out limitations to 
the use of the composite choline signal as a marker of response, which notably 
included a large inter-subject variability in the level of metabolites detected 
using 
1
H-MRS.
14
 Here, we show that tCho level quantification in vivo with 
1
H-
MRS is a sensitive pharmacodynamic marker of a tumor to choline targeted 
treatment. However, this measurement was not per se predictive of the tumor 
response to a treatment as tumors were responsive to sorafenib and not to H89. 
Longitudinal pre- and post-treatment measurements of ADC values were more 
consistent in terms of response as there was a close agreement between ADC 
values, tumor growth and tumor necrosis for both H89 and sorafenib treatments.   
Of note, besides the multiple kinases inhibited by Sorafenib, the drug has 
also shown significant anti-angiogenic properties that could also be responsible for 
changes in tumor ADCw. In this context, we previously showed that, while the 
anti-angiogenic effect of sorafenib can be quantified as soon as 48h post-treatment 
using anti-CD105 antibody, it is not reflected in terms of ADCw at this time point, 
and only becomes significant at day 5.
19,27
 Moreover, tumor cell proliferation 
assessed in vivo using 
18
F-FLT with a similar protocol does significantly increase at 
day 2. All these data do suggest that the anti-angiogenic property of the drug is not 
the major factor responsible for the change in ADCw. Finally, regardless the major 
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factor influencing the change in ADCw in response to treatment with sorafenib, the 
current results do still demonstrate that tCho can be modified with no consecutive 
effect in terms of tumor growth.  
In conclusion, DW-MRI combined with choline spectroscopy may provide a 
useful non-invasive marker of response for choline signaling-targeted therapies, 
with the ultimate goal of improving individualized drug therapy. 
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Figures 
Fig.1  
  
 (A) Longitudinal and individual follow up of total choline to water ratio 
(tCho/water ratio) before and after direct (H89) and indirect (sorafenib) treatments 
targeting choline kinase.  A significant decrease in the choline to water ratio was 
observed after 48 hours of treatment with H89 (*) and with sorafenib (**). (B)  
Ex vivo quantification of PC using mass spectrometry (HPLC-ESI-MS)  in 
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control tumors vs H89 or sorafenib tumors, and in shChKA vs shSCR tumors. 
(C) tCho/water ratio in shChKA group vs shSCR (control) group (with 
confirmation of inhibition of ChKA expression in vitro on MDA-MB-231 cells 
by Western blotting analysis) (D) Typical in vivo 1H-MRS spectra of MDA-
MB-231 tumors:  control shSCR tumor and choline kinase downregulated 
shChKA tumor.  
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Fig.2  
 
(A) Longitudinal and individual follow up of tumor ADCw following 
administration of H89 and sorafenib. A significant decrease in cellularity was 
observed after 5 days of sorafenib treatment. 
(B) Typical ADCw maps and corresponding anatomical MR images of MDA-
MB-231 tumors before (left image) and 5 days after treatment with sorafenib 
(right image). (C) Quantification of H&E staining in H89 or sorafenib treated 
tumors, choline-kinase downregulated (shCHKA) tumors, vs controls.  (D) 
Typical H&E sections of MDA-MB-231 control (left) and 5 days-sorafenib 
treated  tumors (right). 
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Fig.3  
 
(A) Growth delay assays showed a significant tumor growth retardation 10 days 
after administration of sorafenib versus control treatment (*), but not for H89 
versus control. 
(B) A significant delay (***) in tumor growth was observed 52 days after tumor 
induction in MDA-MB-231 shChKA tumors in comparison with control group 
(MDA-MB-231 shSCR).  
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Supplementary methods 
Tumor cells & animal model 
MDA-MB-231 human breast cancer cells were grown in Dulbecco’s modified 
Eagle’s medium containing low glucose, GlutaMAX, pyruvate, 10% fetal 
bovine serum (v/v) and 1% penicillin-streptomycin (v/v). About 10 million cells 
resuspended in 100μl of NaCl 0.9% were injected into the hind limb of 5-6-
week-old female NMRI nude mice. Tumors were allowed to grow up to a 
volume of 200 mm
3
 at which time they were imaged (day 0 or ‘pre-treatment’ 
time point) and treated with Sorafenib, H89, or vehicle. Longitudinal imaging 
was then performed at day 2 and day 5. All in vivo experiments were conducted 
under approval of UCL authorities (Comité d’Ethique Facultaire pour 
l’Expérimentation Animale) according to national animal care regulations.  
Cell transfection 
For lentivirus preparation, HEK293FT cells were transiently transfected with 
lipofectamine using a third-generation lentiviral system. After 24h and 48h, viral 
supernatants were harvested, titrated, and used to infect target MDA-MB-231 
cells. Selection was done with puromycin (2 µg/mL). MDA-MB-231 cells were 
infected with lentivirus containing five short hairpin RNA’s (shRNA) tartgeting 
ChKA (ThermoFisher Scientific ABgene; Epsom, Surrey – United Kingdom). 
The most effective shRNA (ID TRCN0000006050) was selected by western blot 
for in vivo experiments. Inhibition of ChKA in MDA-MB-231 cells was 
compared with cells transduced with shRNA’s with a scrambled sequence 
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(SCR). shRNA tumors were allowed to grow up to a volume of 200 mm
3
 and 
were then imaged, SCR vs shRNA ChKA groups were compared. Reduction in 
choline kinase expression was assessed by western blotting analysis. 
Western Blotting 
To confirm ChKA inhibition in shRNA cells, as well as to confirm the effect of 
sorafenib and H89 on ChKA, western blot analysis was performed on MDA-
MB-231 cells after 2 days of treatment with H89 (5µg/ml of medium) and 
sorafenib (10µg/ml of medium), in comparison with control cells. Cells were 
lysed and proteins were extracted in RIPA buffer. Proteins were separated on 4-
20% gels (Biorad) and transferred to a PVDF membrane for detection with 
rabbit anti-ChKA (Sigma) and mouse anti-β-actin (Sigma) antibodies. 
Peroxidase-conjugated secondary antibodies anti-mouse or anti-rabbit were 
used. Chemiluminescense was visualized using Western lightning plus ECL 
(PerkinElmer). Quantification based on color density of ChKA expression vs B-
actin expression was performed using Image J software. 
Phosphocholine quantification in tumors by HPLC-ESI-MS 
Tumor tissues were homogenized in distilled water (10mg/mL) before adding 
the internal standard (d9-choline, 4 nmol), methanol (1 mL) and chloroform (1 
mL). Following vigorous mixing the samples were centrifuged and the aqueous 
layer containing phosphocholine was recovered and evaporated under a stream 
of N2. The resulting residues were solubilized in 100 µL of mobile phase and 25 
µL were analyzed by HPLC-MS using an LTQ Orbitrap mass spectrometer 
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coupled to and Accela HPLC system (Thermo Fischer Scientific). Analyte 
separation was achieved using an HILIC guard pre-column and an HILIC 
Proshell 120 column (4µm, 4.6 x 150 mm) (Agilent). Separation was achieved 
by isocratic elution (0.4mL/min) using acetonitrile-water (50:50, v/v) containing 
20 mM ammonium formate and adjusted to pH 4.4. An ESI source operated in 
the positive mode was used for the MS analysis. Data were normalized by tumor 
sample weight. 
Histology 
Tumors were excised 24-h after the end of treatment and fixed in 4% 
paraformaldehyde. Samples were paraffin-embedded and sliced in 5 µm-thick 
sections. Tissue slices were stained with hematoxylin and eosin, and 
photographed on a Zeiss MIRAX slide scanner for a global view of necrotic 
tumor areas. Quantification of necrotic regions was obtained using Panoramic 
Viewer and Image J software, and is expressed as % of whole tumor area. For 
that purpose, the percentage of necrosis was determined by detecting the number 
of pixels that satisfy a color and intensity predefined (necrotic), divided by the 
number of pixels in non-necrotic tissue. 
 
Tumor Growth 
At day 0 (mean tumor volume=0.2±0.1cm
3
), tumor-bearing mice were injected 
with sorafenib (40mg/kg/day), H-89 (20mg/kg/day) or vehicle (DMSO, 35µl). 
RESULTS 
Page | 106  
 
Tumor size was assessed using an electronic caliper for 10 days. Tumor 
established with shRNA-transfected cells were monitored for 52 days after 
tumor induction. Tumor volumes were estimated by determining the mean of the 
3 tumor diameters D (mean of length, width and height), using the following 
equation: Tumor volume= 𝜋 ∗ (
𝐷
2
)
2
. 
Statistical Analysis 
Results are shown as means ± standard error of the mean (SEM). Confidence 
intervals (CI) are calculated for a measure of treatment effect. Comparisons 
between groups were made using Student’s t-test or one-way ANOVA (post-hoc 
Dunnett’s multiple comparison test) where appropriate. p-Values ≤ 0.05(*), ≤ 
0.01(**) or ≤ 0.001(***) were considered to be significant. 
 
  
RESULTS 
Page | 107  
 
Supplementary figures 
Sup.Fig.1A 
 
 
Sup.Fig.1B 
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Legend : Fig.1A : Western blotting analysis of ChKA expression in control and 
treated (sorafenib, H89) MDA-MB-231 cells in vitro. Fig.1B : Expression of 
ChKA (normalized to B-actin) is decreased to 49,7%+/- 9,1% of the control 
after treatment with Sorafenib (** ; n=4, independent experiments) and 
71,9%+/- 6,2% of the control after treatment with H89 (* ; n=4, independent 
experiments).  
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Addendum 
Before to start the study, some preliminary experiments were realized to 
evalutate the efficacy of different treatments and to define different time points 
to visualize the treatment effects. During this preliminary phase, 
teatraethylammonium (TEA) an inhibitor of OCT (20mg/kg, intra peritoneal), 
was also tested to evaluate its potential action on the choline cycle. 
 
Longitudinal follow up of total choline to water ratio (tCho/water ratio) before and 
after direct inhibition of choline kinase α using H89 and before and after inhibition 
of organic cation transporters using TEA.  A significant decrease in the choline to 
water ratio was observed after 48 hours of treatment with H89; that was not the 
case for TEA. 
 
  
 
 Tea 
Control 
H89 
Days after treatment 
 
Choline/water 
*100 
RESULTS 
Page | 109  
 
2. 13C-MRS is a method of choice to image metabolic substrates. This 
emerging method is able to assess disease activity and contribute to 
decisions concerning the patient care. In this study, the dynamic 
monitoring of the conversion of hyperpolarized 13C-fumarate into 13C-
malate, and of hyperpolarized 13C-pyruvate into 13C-lactate, is used as 
emerging in vivo markers to evaluate treatment efficacy. 
 
 
 
 
 
 
II Monitoring chemotherapeutic response by hyperpolarized 13C 
-fumarate MRS and diffusion MRI. 
 
Lionel Mignion, Prasanta Dutta, Gary V. Martinez, Parastou Foroutan, Robert J. 
Gillies, Benedicte F. Jordan. 
 
Cancer Research, 2014 Feb 1 ; 74 (3) : 686-694. 
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4.1  Discussion 
 
 This thesis involves the study of “classic” and “emerging” non-invasive 
MR biomarkers of response and their combinations to assess changes induced 
by modulators of the choline cycle. These in vivo techniques monitor changes 
in cellularity, membrane turnover, and cellular metabolism in a human breast 
cancer model.  Tumor size measurement is not always adequate to monitor the 
tumor response to targeted treatments. Indeed, targeted therapies usually 
result in tumor size stabilization rather than in tumor size reduction, reducing 
the sensitivity of standard metrics of response, such as RECIST (Milano, 2011). 
Moreover, after chemotherapy, changes in tumor size can take several weeks 
before to be detectable. Therefore, the identification of more sensitively, non-
invasive biomarkers are needed to guide diagnostic decisions, to predict 
response to therapy or to optimize the schedule and dosage of novels 
therapeutics. Breast MRS is used to distinguish benign and malignant lesions 
improving the accuracy of a MR scan by improving the selectivity. In human 
breast studies, the decrease of tCho suggests successful therapy (Bolan, 2013). 
Diffusion MR imaging provides information about the cell density and can have 
a major role in many clinical situations as: tumor detection and 
characterization; differentiation of abscess from necrotic tumors; follow-up of 
the patient with cancer to monitor and predict treatment response,… 
(Rajeshkannan, 2006 ; Koh, 2007). In clinical oncology, multimodality setting 
can permit to confirm diagnostic or to help to choose the right therapy.  
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4.11  Modulation of the choline pathway 
 
In this work, the choline pathway or Kennedy pathway was studied as a 
predominant pathway for the cellular membrane anabolism and cells 
multiplication in cancer tissues. As stated in the introduction, the study of the 
choline pathway can be very complex with a lot of interactions at different 
levels. Many enzymes have a regulatory role in this pathway and can influence 
positively or negatively the cell membrane formation. All the mechanisms 
regulating the phosphatidylcholine synthesis may be more complex than what’s 
immediately apparent. Also, reciprocal links between the major oncogenic 
pathways and the choline cycle have been established (i.e. with MAPK and PI3K 
pathways). 
In a first study, we measured the total choline from in vivo volume 
localized inside a breast tumor and evaluated the response to targeted 
therapies using proton MR spectroscopy and DW-MRI. tCho levels can be 
determined non-invasively in tumors with 1H-MRS. In vivo “total choline” is 
composed of several different choline metabolites that overlap and contribute 
to this peak. The variations of the total choline value are due to a lot of 
enzymes and it reflects the global tumoral activity, cellular proliferation and 
possibly, malignancy. In our work, this pharmacodynamic parameter was 
suitable to demonstrate if the inhibition of the choline pathway was active or 
not, it was even confirmed with ex vivo mass spectroscopy analysis that 
confirmed reduction in intratumoral phosphocholine levels. In line with these 
findings, inhibition of MAPK signaling with the U0126 MEK inhibitor has been 
reported to cause a drop in intratumoral tCho and phosphocholine levels in 
tumors (Beloueche-Babari, 2005). However, choline MRS was not suited to 
predict the actual response of a tumor to a choline-targeted treatment since 
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reductions in choline levels did not systematically mean a tumor growth 
retardation. Indeed,  when  targeting  ChoK  with  a  direct  inhibitor  (H89),  a  
significant  decrease  of  tCho  was observed  that  was  not  associated  with  a  
drop  of  cellularity  and  a  stabilization  of  tumor  growth. Comparatively, the  
multi-kinase inhibitor sorafenib decreased the tumor content of tCho, which 
preceded decreased cellularity (measured  with  DW-MRI),  necrosis  and,  
ultimately,  a  reduction  of  tumor  size  (which  became significant only 5 days 
post-treatment). As a conclusion of the first part of this work, we can state that 
tCho level quantification in vivo with 1H-MRS is a sensitive pharmacodynamic 
marker of response for choline signaling targeted therapies. However, this 
measurement is not per se predictive of the tumor response to a treatment as 
tumors were responsive to sorafenib and not to H89. Longitudinal  pre-  and  
post-treatment measurements of ADCw values were more consistent in terms 
of response as there was a close agreement between ADCw values, tumor 
growth and tumor necrosis for both H89 and sorafenib treatments. Thus, DW-
MRI combined with choline spectroscopy may provide a useful non-invasive 
marker of response for choline signaling-targeted therapies.  
MRS and DW-MRI methods can present some technical limitations in the 
tumoral context.  These limitations constitute a supplementary reason to 
combine methods to obtain a performing marker of response for choline 
signaling-targeted therapies. 
- The tumoral tissue is generally very heterogeneous and 1H-MRS 
measures the mean of the tCho in a determined voxel. For this reason 
the position of the voxel inside the tumor can influence the mean 
global value of tCho. Multi voxel imaging allows to have a better 
evaluation of the intra-tumoral heterogeneity of choline, yet with a 
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lower signal to noise ratio in each voxel under study. Using this 
method, responses in various areas can be observed after targeted 
therapy.  
 
- The measurement of tCho peak using MRS can be very difficult if the 
lipid peak is large, this problem is relatively frequent in breast cancer. 
 
- There is a large inter-subject variability in the level of metabolites 
detected using 1H-MRS and in the ADCw measured using DW-MRI. For 
this reason, the two methods are adapted to a longitudinal follow up 
of individual tumors before and after treatment. 
 
- Using DW-MRI some artifacts can arise from motion, Eddy currents, 
ghosting and susceptibility effects (Padhani, 2009). Water motion is 
also very sensitive to the local temperature. To reduce a part of these 
artifacts, the tissue of interest is placed in the centrum of the magnet, 
the movements of mice are restricted, the respiration is controlled 
using anesthesia and the temperature of the subject is regulated. For 
translational purposes, standardization procedures and multi-centric 
reproducibility studies still need to be implemented, although the 
technique is widely used in the clinical setting.  
 
a. Choline pathway:  alternative multi-modal approach 
During the process of this thesis we accumulated some non-published 
data that are being discussed here in the context of the monitoring of the 
inhibition of the choline pathway. 
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The initial objective of the thesis was to combine PET (18F choline) and 
choline-MRS data to obtain a complete overview of the choline cycle in-vivo 
before and after modulations of the choline pathway (Fig.27). Indeed, 18F-
choline is described to probe the uptake of choline into the cell whereas 1H-
MRS is assessing the whole total choline tumor pool, with a possibility to assess 
more specifically PCho using 31P-MRS. 
 
 
Fig.26.  Choline pathway and corresponding multi-modal approach. 
 
 In a multi-modal approach, a complementary method to evaluate 
modulations in the free choline pool or on choline transport and intracellular 
choline is indeed Positron Emission Tomography (PET) after administration of 
one of the tracer 18F or 11C-choline. In our work, we used 18F-choline to evaluate 
the choline uptake before and after treatment. Indeed, 18F-choline (half-life 
110min) has great structural similarity with natural choline. The 
Transporters 
Phospho-
lipids 
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pathophysiological basis for the use of choline and its derivates for cancer 
imaging are the elevation of choline levels and the up-regulation of choline 
kinase activity in malignant cells (Kohlfurst, 2009). The first tests were 
performed on breast cancer mice xenografts, but the spatial resolution along 
with the relatively low signal to noise ratio obtained with 18F-choline prevented 
the quantitative analysis of the data. 18F-choline studies were therefore not 
pursued in this work. 
In addition to 1H-MRS, the measurement of PCho via 31P-MRS can be 
performed using single voxel spectroscopy on a double tuned 1H-31P surface 
coil. If the measurement of PCho would be very interesting to evaluate the 
choline kinase activity, our in vivo 31P-MRS data obtained from 7 mm breast 
cancer xenografts presented a limited signal-noise ratio that was too low for 
spectral editing and robust quantification, despite the major interest for this 
technique. Alternatively, ex vivo quantification of PCho was performed using 
mass spectrometry and confirmed in vivo results obtained in terms of tCho 
using 1H-MRS.  
 
b. Choline pathway:  alternative targets 
Besides choline kinase, alternative targets can be considered in the 
choline pathway, including inhibition of choline transport or of choline 
‘recycling’ (fig.28). 
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Fig.27.  Choline pathway and specific inhibitors of the cycle. Adapted from 
Glunde, 2004. 
Pilot experiments involving inhibition of the choline transport as well as 
of choline recycling were performed in the same xenograft tumor model.  We 
could conclude from these preliminary tests that tetra-ethyl ammonium (TEA), 
an inhibitor of the organic cation transporters (OCT) was not able to 
significantly decrease 1H-MRS tCho peak, contrarily to H89. This result can be 
explained by the complexity and the different systems of choline transport. The 
inhibition of OCT is probably not sufficient to impact the tCho level and there 
are probably some phenomena of bypass to compensate the inhibition of a 
specific type of choline transporter. An overall prominence of the transporters 
on kinases in the increase of tCho peak is present in specific models as 
rhabdomyosarcoma (Rommel, 2012). However, on MDA-MB-231 breast cancer 
cells, ChoK has the most important role in the increase of the tCho level 
TEA 
H89 D609 
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(Glunde, 2004). This can explain a part of the lack of response after TEA 
treatment. 
 
Fig.28. : (A) Evolution of total choline to water ratio before and after H89 
treatment inhibiting choline kinase and TEA treatment inhibiting choline 
transport. A significant decrease in the choline to water ratio is observed after 
48 hours of treatment with H89 (*). (B) Tumor ADCw following administration 
of H89 and TEA. 
 
In an effort to identify a choline cycle inhibitor that would have a direct 
impact on tumor progression in vivo, the more recent  inhibitor of choline 
‘recycling’, D609,  was tested in vivo. Actions of this inhibitor are attributed to 
the inhibition of phosphatidylcholine-specific phospholipase C (PC-PLC). This 
competitive PC-PLC inhibitor (D609) blocks cell proliferation in vitro and 
prevents these cells from entering in the S phase under growth factor 
stimulation (Ioro,2010). In our hands, this inhibitor had no significant effects in 
vivo on the tumor volume after 10 days of treatment in the breast cancer 
xenografts.  These results were unpredictable because proliferation arrest, 
changes in cell morphology and formation of cytosolic lipid bodies typical of cell 
differentiation were induced by D609 in breast cancer cells (Abalsamo, 2012). 
However, another study indicated that inhibition of PC-PLC by D609 enhances 
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phospholipase D (PLD) activity in UMR-106 osteoblastic cells either due to a 
compensatory effect or that D609 directly increased PLD activity (Singh, 
2000). It is also possible that this targeted treatment has no direct effect on the 
tumor size, as it is the case with the choline kinase inhibitor H89.  
 
4.12 Emerging imaging markers of response based on the 
dynamic monitoring of metabolism 
 
In a second part of the work, the combination of DNP and MRI was 
considered since it can image non-invasively the carbon metabolism in living 
system (Golman, 2006). There is a need for non-invasive imaging technique to 
develop imaging method that can detect metabolic transformations and 
treatment response before there is any change in tumor size. The 
transformation of 13C-Fumarate to 13C-Malate provides positive contrast and is 
suggested as a marker of cell death (Gallagher, 2009). The rate of labelled 
malate production showed good correlation with the level of tumor cell 
necrosis (Gallagher, 2009). In this study we showed an increase (2.8 folds) of 
the malate/fumarate ratio after Sorafenib treatment; these results are 
confirmed with the increase of necrosis measured by DW-MRI and H&E 
analysis. The net change in 13C-fumarate conversion into malate marker was 
even more sensitive than DW-MRI. These results confirm the data of Bohndiek 
et al who showed that the changes in fumarate conversion were earlier and 
more sensitive than the change in ADCw in lymphoma tumors treated with 
combrestatin-A4-phosphate (Bohndiek, 2010). 
The monitoring of pyruvate to lactate ratio did not show any sensitivity 
to treatment with sorafenib in this study on MDA-MB-231 xenografts. The 13C 
isotope exchange flux between pyruvate and lactate is under equilibrium. 
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However lactate can be used as a biomarker of cancer aggressiveness, 
metastatic potential and treatment response (Sriram, 2015). A factor that could 
be involved in this lack of response to treatment is the potential normalization 
effect of sorafenib. Indeed, daily oral administration of this drug for 5 days 
strongly decreased the number and area of microvessels in the sorafenib-
treated tumors, showing significant inhibition of angiogenesis (Wilhelm, 2004). 
Potential vessel normalization could contribute to an increase in delivery of 
pyruvate at day 2 of 5, which could in turn compensate for a potential decrease 
in the pyruvate-to-lactate ratio.  
Co-hyperpolarised pyruvate and fumarate preparations could not be 
used in vivo as malate production was masked by overlapping signals from 
lactate and pyruvate hydrate formed from labelled pyruvate (Witney, 2010). 
However simultaneous evaluation of enzymatic pathways using multi-
compound polarization would be a powerful method of probing multiple 
metabolic pathways in a single MR scan lasting only seconds (Wilson, 2010). 
Using this technique, information on metabolism, pH, necrosis and perfusion 
can be assessed simultaneously using 13C-pyruvic acid, 13C-sodium bicarbonate, 
13C-fumaric acid, and 13C-urea with high levels of solution polarization (Wilson, 
2010). Multi-compound polarization is a powerful method of probing multiple 
metabolic pathways. 
 DNP technique has been successfully used in pilot clinical studies at the 
University of California in San Francisco in prostate cancer. This recent first in 
man clinical trial utilized hyperpolarized 13C-MR imaging. The goal of this study 
was to confirm the clinical potential and the feasibility of the technique in 
humans. No adverse effect or dose limiting toxicities have been reported. The 
results were extremely promising not only to confirm the safety of the agent 
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but also to show elevated 13C-lactate/13C-pyruvate ratio in cancerous regions 
(Nelson, 2013). This success opens a new perspective for hyperpolarized 13C-
imaging (Yen, 2011). 
 In pre-clinical disease models, several of the key metabolic shifts found in 
cancer, among which accelerated glycolysis, can be highlighted using 
hyperpolarized 13C enriched substrates. Indeed, several cancers have a 
preference for aerobic glycolysis, whereby the pyruvate produced by glycolysis 
is converted to lactate, rather than entering in the Krebs cycle (Warburg effect) 
(Wilson, 2014). The hyperpolarization has the potential to revolutionize the 
way we use MR imaging. In particular, hyperpolarization addresses some of the 
intrinsic limitations of 1H-MRS, including low sensitivity, overlap of key 
resonances, and lack of information about metabolism (Wilson, 2014). The use 
of 1H and hyperpolarized 13C-spectroscopy can help in the early diagnosis of 
cancer or to highlight an early treatment response. Future efforts in humans 
will be driven by new hyperpolarized biomarker probes identification and 
validation, improved methods for polarization and delivery of 13C-substrates. 
a. Place of hyperpolarized 13C-spectroscopy vs PET imaging  
FDG-PET is a reference method to predict pathological response in 
patients with breast cancer following chemotherapy (Biersack, 2004). However, 
with this method, the presence of infected or inflamed tissue can mask changes 
in tumor FDG uptake (Strauss, 1996) and patient received radiation doses. 
Recently, a combination of hyperpolarized 13C-pyruvate magnetic resonance 
spectroscopic imaging and FDG-PET imaging was performed on a canine cancer 
patient using a clinical PET-MRI scanner. This study showed the co-localization 
of increased 13C-lactate production and high 18F-FDG uptake on PET (Gutte, 
2015). This is in agreement with the fact that glycolysis and production of 
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lactate are increased in tumor cells compared to normal cells. PET alone is 
sometimes unable to localize small tumors or confirm whether FDG uptake in 
unusual sites reflects tumor or nontumor (Griffeth 2005).The combination of 
hyperpolarized 13C-pyruvate MRS imaging and 18F-FDG PET imaging may be 
valuable to discriminate high 18F-FDG uptake due to activity in a muscle than 
high 18F-FDG uptake due to Warburg effect in a tumor which will be 
accompanied by hight 13C-lactate production. The hyperpolarized 13C-pyruvate 
technique can be valuable with specific cancer localization where the 18F-FDG 
uptake is not sufficient as in low-grade lymphoma.  
  
DISCUSSIONS AND PERSPECTIVES 
Page | 133  
 
4.2  General conclusion 
 
The aim of the thesis was to assess response to modulations of the 
choline pathway in the context of the cholinic tumor phenotype. Conventional 
measurements like anatomically based endpoints may be inadequate to 
monitor the tumor response to targeted agents that usually do not result in 
tumor shrinkage while used in monotherapy. Therefore, the identification of 
more sensitively, non-invasive biomarkers are needed to optimize the schedule 
and dosage of novels therapeutics. The results illustrate that the assessment of 
total choline with 1H-MRS is able to confirm the inhibition of the target but is 
not sufficient to predict tumor response to the targeted treatment. Adding 
DW-MRI as a marker of tumor response to choline inhibition improves 
specificity of the monitoring. In addition, 13C-magnetic resonance spectroscopy 
and the detection of hyperpolarized 13C-fumarate to 13C-malate conversion has 
been suggested as a marker of cell death and treatment response in tumors. 
We showed here that hyperpolarized 13C-fumarate, detected by 13C-MRS, could 
constitute a new early in vivo marker of response to Sorafenib (MAPK 
inhibitor). The Sorafenib treatment targets a lot of kinases and its multi kinase 
action is closer to a non specific chemotherapeutic agent than to a very specific 
targeted treatment. It would be interesting to monitor the use of a more 
specific ChK inhibitor as MN-58b using 13C fumarate. However, using Sorafenib 
treatment, the level of tumor cell necrosis after treatment has been described 
as a good prognostic indicator for treatment outcome in the absence of any 
change in tumor size. Our results show that the net change in 13C-fumarate 
conversion into malate marker was even more sensitive than DW-MRI.  
In conclusion, our studies illustrate that: (i) the total choline 1H-MRS 
marker can constitute a pharmacodynamic marker of choline targeted 
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therapies, but does not presume the actual response to therapy, (ii) the 
combination of diffusion MRI and choline spectroscopy can be considered as a 
marker of response to choline targeted therapies, and (iii) the follow up of the 
metabolic ratio of 13C-fumurate into 13C-malate can be considered as an 
emerging marker of response to targeted therapies, with an improved 
sensitivity while compared with Diffusion-MRI.  
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4.3  Perspectives 
 
 4.31  In terms of inhibition of the choline pathway 
 
The use of more specific and more efficient inhibitors of the choline 
pathway should be considered, including a specific and very efficient inhibitor 
of ChoK such as MN58b, as described in the introduction, but that is not 
commercially available. In the purpose, using in silico screening for small 
molecules that may interact with the choline kinase-α substrate binding 
domain, Clem et al. in 2011 identified a novel competitive inhibitor, N-(3,5-
dimethylphenyl)-2-[[5-(4-ethylphenyl)-1H-1,2,4-triazol-3-yl]sulfanyl] acetamide 
(termed CK37) that inhibits purified recombinant human choline kinase-α 
activity, reduced the steady-state concentration of phosphocholine in 
transformed cells, and selectively suppressed the growth of neoplastic cells 
relative to normal epithelial cells. Interestingly, CK37 suppresses mitogen-
activated protein kinase and phosphatidylinositol 3-kinase/AKT signaling and 
significantly decreased tumor growth in a lung tumor xenograft mouse model, 
suppressed tumor phosphocholine, and diminished activating phosphorylations 
of extracellular signal-regulated kinase and AKT in vivo. Also, more recently, in 
a T-lymphoma xenograft murine model, Chokα inhibitor CK37 remarkably 
retarded tumor growth, suppressed Ras-AKT/ERK signaling, increased 
lysophosphatidylcholine levels and induced in situ cell apoptosis/necropotosis 
(Xiong, 2015). It seems particularly relevant to monitor the effects of this 
choline kinase inhibitor in our breast cancer xenograft model using choline 
MRS, DW-MRI and 13C-MRS hyperpolarized markers, since it is also inhibiting 
important signaling pathways in oncology, ie. MAPK and PI3K, that have been 
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described to be dependent on the choline cycle and more specifically on 
phosphatidic acid (Yalcin, 2010).  
Other enzymes and steps of the choline pathway could be targeted, 
including using potent PC-PLC and PC-PLD inhibitors. There are some evidence 
that PC-PLC is implicated in metabolism, proliferation, and differentiation in 
mammalian cells (Spadaro, 2008). Moreover, increased PC-PLC activity was 
reported in breast tumor cells (Glunde, 2004). These data suggest the possible 
use of PC-PLC as a target for anti-cancer therapy. D609, a putatively selective 
antagonist of PC-PLC, increases PLD activity when PLC is inhibited in 
osteoblastic cells. This side effect might influence the downstream response to 
treatment (Singh, 2000). A combination of treatments should be used to inhibit 
PC-PLC and PC-PLD in the same time. Simultaneous use of a specific PLD 
inhibitor (Halopemide for example) with D-609 can be interesting for further 
studies. This combination of inhibitors is very interesting in theory; however 
the use of this combination of treatment can produce some neurologics side 
effects and mental disorders because halopemide a psychotropic agent, a 
analogue of neuroleptics (Loonen, 1985). For this reason a total inhibition of 
phospholipase C and D using this combination of treatments is not 
recommended, unless less toxic agents can be found. 
Finally, recent studies strongly suggest the interest of combining choline 
kinase inhibition along with PLD1 inhibition. Indeed, the group of Z. Buhjwalla 
(Gadiya, 2014) reported a strong correlation between expression of Chokα and 
PLD1 with breast cancer malignancy. Data from patient samples established an 
association between estrogen receptor status and Chokα and PLD1 expression. 
In addition, these two enzymes were found to be interactive. Downregulation 
of Chokα with siRNA increased PLD1 expression, and downregulation of PLD1 
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increased Chokα expression. Simultaneous silencing of PLD1 and Chokα in 
MDA-MB-231 cells increased apoptosis as detected by the TUNEL assay.  
These data provide new insights into choline phospholipid metabolism of 
breast cancer, and support multiple targeting of enzymes in choline 
phospholipid metabolism as a strategy for treatment. 
4.32  In terms of acquisitions quality 
 
For 1H localized single voxel spectroscopy the new software “paravision 
6” of bruker offers the possibility to realize adjustments and spectrum on 
circular regions of interest, contrarily to the version used in this study that only 
allows to define cubic regions of interest that have to be placed properly inside 
the tumor. This improvement can facilitate the acquisition of a spectrum from a 
tumor, which is generally not cubic.  
For 13C-acquisitions, optimized sequences for localized 13C-spectroscopy 
would be required. Until now, the placement of the subcutaneous tumor was 
performed in order to be able to delimit a large slice covering the whole tumor 
without any other tissue interaction. Many groups have implemented 
optimized localized sequences with improved acquisition times (Nelson, 
Ozhinsky, 2013).  
In addition, the optimization of localized 31P-spectroscopy, to get a higher 
signal to noise ratio would be useful tool to monitor the transformation of 
choline in phosphocholine. 
A major limitation of hyperpolarized magnetization is its unrecoverable 
decay, due not only to T1 relaxation but also to radio-frequency excitation. 
Some improvements can be done by eliminating the loss of hyperpolarized 13C-
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pyruvate magnetization due to radio frequency excitation. In this excitation 
scheme, the use of a spectral selective radio frequency pulse is involved to 
specifically exclude the excitation of 13C-pyruvate, while uniformly exciting the 
key metabolites of interest (13C-lactate, 13C-alanine and 13C-pyruvate-hydrate). 
The signal from downstream metabolite pools will be increased in terms of 
signal to noise ratio and lifetime (Chen, 2015). In the hyperpolarized 
applications, the life time is a critical point especially at high field. 
 
4.33  In terms of techniques or post-processing 
 
There is now considerable interest in applying more sophisticated 
mathematical models to DW-MRI data to extract quantitative parameters that 
reflect tissue microcapillary perfusion. By acquiring DW-MRI images using 
multiple b values (typically 6 or more), the DW-MRI data may be fitted using a 
biexponential mathematical model. Using such an approach, quantitative 
parameters that reflect vascular flow and tissue diffusivity can be derived. It is 
still unclear today whether such an approach does improve the assessment of 
drug effects and further studies are warranted (Afaq, 2010). 
The use of hyperpolarized 13C or 15N choline can be very interesting to 
follow the choline metabolism. This approach can be potentially used as an 
imaging biomarker of cancer similar to choline positron emission tomography 
tracers to image and stage a cancer (Shchepin, 2013). In this context, 
hyperpolarized choline imaging with MRI was recently shown to be feasible 
using a stable isotope labeled choline analog (CMP1 or 1,1,2,2-D4 , 1-(13) 
C]choline chloride) (Friesen-Waldner, 2015). In addition, an earlier study 
demonstrated the feasibility of detecting hyperpolarized 15N labeled choline in 
vivo in a rat head at 9.4 T (Cudalbu, 2010). 
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Finally, spectroscopic imaging, both for 1H and 13C MRS could be used to 
probe tumor heterogeneity of response. 
Nowadays, no single technique is completely able to highlight early 
treatment response with high sensitivity and specificity because each of these 
techniques has its limitations. The use of hyperpolarized 13C spectroscopy in 
combination with 1H spectroscopy and DW-MRI will furnish complementary 
informations to improve the monitoring of cancer response to treatment. In 
the future, multimodal non-invasive imaging will probably allow a more 
accurate diagnostic and treatment individualization by early prediction of 
optimal therapeutic response.  
 
4.34  Future clinical applications 
  
 While considering future potential clinical applications of this work, 
several aspects have to be considered, including technical implementation of 
the technologies into the clinical setting, identification of the real added value 
of using early markers of response in order to improve individualized therapy, 
and consideration of toxic secondary effects of single treatments as well as 
added toxicities in treatment combinations. All three aspects must be 
addressed before any translational relevance can be established. 
 The recent development of sterile polarizer systems permits the 
translation of the use of the hyperpolarized technology to the clinical practices. 
A first in human study has been already performed at the University of 
California in San Francisco (Nelson, 2013b). In this study, the potential of 
hyperpolarized pyruvate to stage a prostate cancer and to differentiate 
malignant versus benign tissue has been successfully investigated.  During this 
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study, no dose-limiting toxicities were observed for 13C pyruvate confirming the 
safety of the agent. This first in human’s success opens the doors for other 
developpements to more diverse populations of cancer patients and to other 
applications as the assessing of a treatment effect. Hyperpolarized 13C 
metabolic imaging may be valuable to precise the initial diagnostic and to 
monitor the efficacy of a therapy. For this last goal, a comparison of the 
lactate/pyruvate or malate/fumarate ratio before and after a treatment could 
be considered to assess treatment efficacy. These imaging biomarkers could 
therefore aid in the diagnosis, prognosis, and monitoring of tumors. With 
respect to drug development, the choice of the best targeted therapy for each 
type of tumor type  could be facilitated by the use of hyperpolarized 13C-MRS 
markers .  
 A more straightforward clinical application is proton spectroscopy in 
humans that has already shown a role in predicting prognostic indicators of 
tumor aggressiveness in patients, including in breast cancer patients (Shin, 
2012). The choline concentration is associated with biologic aggressiveness; 
difference in choline detection between invasive and in situ cancers may reflect 
the distinct histopathologic and biologic subtypes of breast cancer (Yeung, 
2002). Total choline content measured by MRS is a non-invasive biomarker of 
cell proliferation and is associated with tumor aggressiveness. Morover the 
spectroscopic imaging can furnish a map of the concentration of the total 
choline compounds inside the tumor. This “choline level” map can help to 
characterize different area in the tumor and to predict the response or non 
response of each area to a defined treatment. The use of spectroscopy in 
addition to the traditional breast MRI could provide a non-invasive accurate 
characterization of the tumor and could help to adapt the treatment.  
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In this thesis, differences in choline content and apparent diffusion 
coefficient before and after a phamacological treatment were recorded using 
single voxel magnetic resonance spectroscopy and diffusion weighted imaging 
respectively. These two methods can be directly used in the clinic using a 
similar protocol to assess treatment efficacy very early after the beginning of 
the therapy. Depending of the molecular characteristics and the agressiviness 
of the tumor, a targeted treatment can be chosen and its efficacy can be 
assessed quite early after the first administration (i.e. several days) using 
choline spectroscopy and diffusion. These data should be compared with data 
before any treatment to see the early evolution of tumor. Moreover, an 
elevated basal level of choline could be tested as a prognostic biomarker to 
differentiate sensitive and resistant tumor to a defined treatment. However, 
converting these results into a clinically usefull response indicator has a long 
way to go, it requires the identification and validation of reliable threshold 
values that may be able to distinguish between responders and non-responders 
(van Asten, 2015). It is necessary to validate these findings in further clinical 
studies to have an individual and optimal therapy for the right patient. 
 In order to clearly determine if early imaging markers of response could 
be an added value in treatment individualization, randomized studies using 
imaging and spectroscopic markers should be designed, involving a 
comparision of a group for which the treatment is shifted to a ‘rescue’ therapy 
when imaging markers do not show any early tumor change versus a group that 
keeps the initial treatment. This trial should therefore be performed on a 
tumor type that has more than one therapeutic option. In the purpose, breast 
cancer patients could be considered for this trial. This study design would help 
to determine if the use of imaging markers to switch therapy very early in the 
treatment course could have a real impact on patient outcome.  Moreover, 
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sparing patients from futile cycles of therapy could also be an endpoint of such 
a study, while considering the numerous side effects of anti-cancer treatments, 
as well as the cost of such therapies. If successful, this trial would constitue the 
first objective finding showing that a proper use of early imaging biomarkers 
could be a step towards a better individualized therapy, and possibly meet 
critical clinical needs in oncology. 
Considering the drugs used in the current study, the toxicity profile of 
Sorafenib does certainly not make it a good candidate for proof of concept 
imaging markers studies in the clinical setting. Due to its multiple targets, 
Sorafenib induces mostly cardiac, dermatological, and gastro-intestinal 
toxicities. Therefore, the choice of a more targeted agent would be judicious. 
Regarding specific ChoKα inhibitors, they have recently entered clinical trials as 
a novel antitumor strategy. If HC-3 is well known to induce neurotoxicity, 
second generation choline kinase inhibitors (Mn58B, TCD717) have been 
designed to decrease neurotoxicity (de la Cueva, 2013). In the purpose, TCD717 
has been tested in a first Phase I multi-centric clinical trial in advanced cancer 
patients between 2010 and 2014 (clinical trial of Brahmer Julie R, Johns 
Hopkins University) with no published results at this stage.  
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